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ZUSAMMENFASSUNG 
 
Zusammenfassung  
Typ I Allergie, eine genetisch determinierte Hypersensitivitätsreaktion, ist 
charakterisiert durch die Produktion von IgE Antikörpern gegen per se harmlose 
Antigene, auch Allergene (z.B.: inhalative Allergene) genannt. Die Sensibilisierung 
gegen respiratorische Allergene findet bereits früh in der Kindheit statt und führt zu 
allergischen Immunreaktionen. Nicht behandelt können milde Ausprägungen von 
Allergien (z.B.: Allergische Rhinokonjunktivitis) zu schweren Symptomen, wie 
Allergischem Asthma und Atopischer Dermatitis führen. Die zentrale Rolle von IgE 
Antikörpern in der Allergenerkennung und in der Aktivierung von Effektorzellen ist gut 
untersucht. Jedoch sind die immunologischen Mechanismen, die zu chronischen 
allergischen Manifestationen wie Atopischer Dermatitis, einer chronischen 
entzündlichen Hauterkrankung, führen, noch nicht vollständig geklärt. Einerseits 
scheinen IgE Antikörper an diesen chronischen Manifestationen beteiligt zu sein, da 
gezeigt werden konnte, dass IgE Antikörper Allergene T-Zellen präsentieren und 
dadurch eine starke T-Zell-Antwort induzieren. Andererseits wurde demonstriert, 
dass nicht-IgE-bindende Allergen-basierende Peptide T-Zellen aktivieren und 
dadurch Spätphasereaktionen hervorrufen können.  
Anhand des Modellsystems Birkenpollenallergie, einer der häufigsten 
respiratorischen Allergien in Nord- und Mitteleuropa, und anhand des 
Birkenpollenhauptallergens, Bet v 1, liegt ein Schwerpunkt der Dissertation darin, die 
Beteiligung von IgE- und nicht-IgE-mediierten Effekten an chronischen allergischen 
Entzündungsreaktionen zu analysieren. Der zweite Teil der Arbeit untersucht 
Ansätze zur Verbesserung der Immuntherapie von Birkenpollenallergie. 
Das erste Kapitel der Dissertation belegt die wichtige Rolle, die nicht-IgE-mediierte 
Reaktionen in chronischen allergischen Hautentzündungsreaktionen in Patienten mit 
Atopischer Dermatitis spielen. Das zweite Kapitel untersucht die biochemischen und 
immunologischen Eigenschaften eines „besonderen“ hypoallergenen Bet v 1 
Derivats, nämlich des Bet v 1 Trimers. Das dritte Kapitel beschreibt die Anwendung 
einer neuen Strategie, die auf der molekularen Wiederzusammenfügung von 
Allergen Fragmenten beruht, zur Entwicklung eines hypoallergenen Bet v 1 Derivats. 
Dieses Derivat könnte zur verbesserten Immuntherapie von Birkenpollenallergie 
eingesetzt werden. 
 
 
SUMMARY 
 
Summary 
Type I allergy, a genetically determined hypersensitivity disease is characterized by 
the production of IgE antibodies against per se harmless antigens, called allergens 
(e.g., inhalant allergens). Allergic sensitization to respiratory allergens takes place 
early in life leading to an allergic immune response. Untreated, mild form of 
respiratory allergy (e.g., allergic rhinoconjunctivitis) can progress to severe 
manifestations such as allergic asthma or atopic dermatitis. The central role of IgE 
antibodies in the allergen-recognition and subsequent activation of effector cells is 
well established. However, the underlying pathomechanisms involved in chronic 
allergic manifestations such as atopic dermatitis, a chronic inflammatory skin 
disorder, are not completely understood. One the one hand, IgE antibodies seems to 
be involved in these chronic manifestations because it has been demonstrated that 
IgE facilitates the presentation of allergens to T cells resulting in a strong T cell 
activation. On the other hand it has also been shown that allergen-derived peptides 
without IgE binding capacity can activate T cells and induce late inflammatory 
responses. 
Taking birch pollen allergy, one of the most common forms of respiratory allergy in 
northern and middle Europe, and the major birch pollen allergen, Bet v 1, as model 
systems, one part of this thesis focuses on the contribution of IgE- versus non-IgE-
mediated effects to chronic allergic inflammation, and the second part investigates 
approaches for improving immunotherapy of birch pollen allergy. 
The first chapter of the thesis provides evidence for an important role of non-IgE-
mediated reactions in chronic allergic skin inflammation in patients with atopic 
dermatitis. The second chapter investigates the biochemical and immunological 
characteristics of an unusual hypoallergenic derivative of Bet v 1, i.e., a recombinant
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Bet v 1 trimer, and the third part describes the application of a strategy based on 
rational molecular reassembly for conversion of Bet v 1 into hypoallergenic derivative 
molecules, which can represent potential candidates for immunotherapy of birch 
pollen allergy. 
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Aims of the thesis 
Atopic dermatitis is a chronic inflammatory skin disorder affecting about 3-10% of 
individuals suffering from IgE-mediated allergies. It is well established that allergen-
recognition by IgE antibodies initiates acute allergic manifestation by activation of 
mast cells and basophils. However the contribution of IgE-mediated versus non-IgE-
mediated mechanisms to chronic allergic inflammation is a matter of controversy. A 
role of IgE-mediated mechanisms has been show by the fact that IgE-facilitated 
presentation of allergens leads to strong T cell activation. In contrast it has also been 
shown that non-IgE-reactive peptides can induce allergic inflammation by activation 
of T-cells and in that way can induce T cell-dependent late phase inflammatory 
responses. 
The aim of this thesis was to use the defined recombinant Bet v 1 allergen and the  
non-IgE-reactive recombinant Bet v 1 fragments, produced by genetic engineering, to 
dissect the contribution of IgE- versus non-IgE-mediated mechanisms to chronic 
allergic inflammation. For this purpose, in chapter 2 the fully IgE-reactive 
recombinant Bet v 1 (aa 1-160) molecule and the non-IgE-reactive rBet v 1 fragments 
(Bet v 1aF1: aa 1-73; Bet v 1aF2: aa 74-160) were used for in vivo skin prick testing 
and atopy patch testing in birch pollen allergic patients with and without atopic 
dermatitis. This study provides evidence for an important role of non-IgE-mediated 
reactions in chronic allergic skin inflammation in patients with atopic dermatitis, a 
finding that may have implications for the selection of therapy strategies. 
Moreover, this thesis aimed for the generation, purification and characterization of 
hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, for improvement 
of specific immunotherapy.
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In chapter 3, the biochemical and immunological behavior of an unusual 
hypoallergenic derivative of Bet v 1, i.e., a recombinant Bet v 1 trimer, was 
investigated. The results revealed that  in contrast to all other previously described 
hypoallergenic derivatives, where reduction of the allergic activity has been obtained 
by destruction of IgE epitopes, the Bet v 1 trimer represents a hypoallergenic allergen 
derivative due to an altered presentation and/or orientation of IgE epitopes. 
Chapter 4 describes the application of a strategy based on rational molecular 
reassembly for conversion of Bet v 1 into hypoallergenic derivative molecules. We 
generated three hypoallergenic rBet v 1 derivatives and demonstrated that 
immunization with these reassembled molecules, which lacked IgE reactivity and 
inhibited allergenic activity, could induce IgG antibodies which recognized Bet v 1 
and strongly inhibited patients’ IgE binding to Bet v 1. These results demonstrated 
that our hypoallergenic rBet v 1 derivatives represent promising candidates for the 
treatment of birch pollen allergy. The strategy we used may not only contribute to the  
generation of new allergy vaccines but may also be applied for induction of mucosal 
tolerance, for gene therapy and genetic immunization protocols.
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1. Introduction 
1.1 History of allergology 
Although allergic diseases is described by some authors as “the epidemic of the 21st 
century”, allergic reactions and classical symptoms of allergies (i.e., swelling of the 
nasal mucosa, redness and itching of the conjunctiva, urticaria, abdominal pain, 
coughing and sneezing) are known for a very long time. It was in 1656 that the 
French physician Pierre Borel conducted the first scientific allergy test placing some 
egg material on the skin of one of his patient, which he suspected to be allergic to 
egg. Consequently blisters appeared on the skin of the patient. In 1819 a British 
pysician, John Bostock, described the affection of eyes and chest caused by fresh 
hay as Catarrhus aestivus and this later gave origin to the term hay fever. In 1873 
another British doctor named Charles Blackley (Figure 1) could demonstrate that 
pollen plays a important role in the pathogenesis of allergy. To investigate his own 
hayfever, Blackley applied pollen through a small break in his skin and demonstrated 
that pollen extract could induce wheal and flare skin response. Moreover, he also 
demonstrated that pollen grains placed into the nose could induce rhinitis. In 1903 
Portier and Richet found that immunization of dogs with increasing doses of the 
jellyfish Physalia toxin could sensitize them so that a second injection of the same 
protein would cause breathing difficulty, influx of fluid into the lungs and death. The 
term anaphylaxis was used by them to describe this opposite phenomenon of 
prophylaxis. Later it became clear that anaphylaxis occurs when allergens enter into 
the circulation of patients with immediate hypersensitivity. 
It was in 1906 that the Austrian pediatrician Clemens von Pirquet (1874-1929) 
(Figure 2) introduced the term “allergy”, coined from the greek words “allos” meaning 
“changed” and “ergos” meaning “action”, as an “altered capacity of the body to react 
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to a foreign substance“ 1. Currently, allergy is defined as a “hypersensitivity reaction 
initiated by specific immunologic mechanisms” 2. In 1911, Leonard Noon and John 
Freeman developed the method of desensitisation defined as “consisting injecting 
increasing doses of an extract of pollen subcutaneously until the hypersensitivity 
reaction was diminished or abolished” 3, and helped to establish the basis for 
immunotherapy. In 1921, Prausnitz and Kuestner provided the first direct evidence 
that immediate skin hyperreactivity could be passively transferred by transferring 
serum from a fish allergic individual to a non-allergic person, which later presented 
skin reaction after administration of fish extract. Thus they postulated that an 
allergen-specific serum factor “reagin” exists. It took until 1967 for the factor referred 
as “reagin” to be biochemically characterized by Kimishige and Teruko Ishizaka 
(Figure 3) and to be classified as a new class of immunoglobulin, the immunoglobulin 
E (IgE). In 1937, Daniel Bovet demonstrated that antihistamines protect against 
symptoms of anaphylaxis and later in 1948 Philip Hench and Edward Kendall 
introduced corticosteroids in the treatment of asthma and both immediate and 
delayed allergic reactions, significantly improving the quality of live of allergic 
patients. In 1953, James Riley and Geoffrey West demonstrated that mast cell 
degranulation is the major source of histamine in the body and contributed to the 
understanding of inflammatory and allergic reactions. 
In 1963, Coombs and Gell classified allergy into four types according to the 
pathophysiological mechanisms involved 4: 
Type I or immediate hypersensitivity: characterized by the production of IgE 
antibodies (see 1.2.1);  
Type II or antibody-mediated hypersensitivity: occurs when IgG or IgM 
antibodies bind surface antigens present on cells of the body leading to the 
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destruction of the cell by activating complement or by antibody-dependent 
cytotoxicity;  
Type III or immune complex disease: occurs when excess immune complexes 
are formed in the circulation that cannot be cleared by macrophages or other cells, 
resulting in inflammation and tissue destruction; 
Type IV or delayed-type hypersensitivity: a T cell-mediated inflammatory 
response rather than antibody responses to antigens. 
One of the recent important event in the history of allergy was the identification of 
leukotrienes by Begnt Samuelsson (Figure 4), that play key roles in allergy, asthma 
and inflammatory diseases. 
The understanding of pathomechanisms underlying hypersensitivity reactions has 
increased significantly during the last decades 5 and its mechanisms are still 
extensively studied because many diseases related to allergy have increased in 
Western world over the past decades. 
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                                                          Figure 2. Clemens von Pirquet 
                                                    coined  the term “allergy”. 
 Figure 1. Charles Blackley      
 performed allergy test by putting 
 pollen directly into a cut in his skin. 
 
 
 
 
                                                                   
        Figure 3. Kimishige Ishizaka (left) and Teruko Ishizaka (right) 
 characterized immunoglobulin E in the serum of allergic   
patients. 
 
 
 
 
 
  Figure 4. Begnt Samuelsson discovered the leukotrienes. 
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1.2 Allergic disease 
1.2.1 IgE-mediated Type I allergy 
IgE-mediated allergies, a type I hypersensitivity with complex genetic background 
caused by IgE responses to harmless environmental antigens, affect approximately 
25 % of the population in industrialized countries 5, 6. In sensitized allergic patients 
IgE recognition of allergens, which per se are generally harmless antigens, leads to 
the formation of IgE allergen immune complexes that activate a variety of immune 
cells involved in allergic inflammation 7-9. Allergic inflammation can occur in different 
target organs when an allergen crosslinks IgE antibodies bound to the high-affinity Fc 
receptor (FcεRI) on the mast cells resulting in the release of biological mediators 
(e.g., histamine) and pro-inflammatory cytokines, and causes symptoms of allergic 
rhinoconjunctivitis, asthma, dermatitis, food allergy and life-threatening systemic 
anaphylaxis, depending on the routes of allergen exposure and the type of allergens 
against which patients are sensitized. This immediate allergic reaction caused by 
mast-cell degranulation appears shortly after contact to the allergen and can be 
followed by late-phase responses, which may ensue some hours later and involve 
recruitment of other effector cells, in particularly Th2 lymphocytes, eosinophils and 
basophils (see 1.2.4). In addition, IgE also plays a important role in the pathogenesis 
of atopic dermatitis (see 1.2.5). 
 
1.2.2 The role of allergens 
An allergen is defined as an “antigen causing allergic disease” 2 and the question 
“What makes an antigen an allergen?” has not been satisfactorily answered yet. 
Allergens may be derived from different sources (e.g., pollen, food, animal dander, 
mites, moulds, venoms) and mainly represent highly water-soluble proteins or 
 15
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glycoproteins with molecular masses between 5-80 kDa, however no common 
structure or biological properties could be identified which would predict their 
allergenic nature 7. Much effort has been put into the characterization in terms of 
structural, molecular and immunological properties of some important allergens, for 
example Bet v 1 from birch pollen (Betula verrucosa), because pure and well 
characterized allergen preparations are prerequisites for allergy diagnosis and 
successful immunotherapy 10-12. The induction of IgE responses by antigens is 
related to the concentration, the route of entry, or the particle size in case of 
aeroallergens 13, 14.  Additionally, epitope mapping of respiratory allergens (e.g., 
pollens) indicated that IgE recognizes mainly conformational epitopes 7. 
 
Natural and recombinant allergens 
Natural allergen extracts are usually used for allergy diagnosis and therapy. With the 
development of molecular biological techniques it became possible to produce 
allergens as recombinant proteins. Recombinant allergens should equal their purified 
natural counterparts, when used for diagnostics purposes. Recombinant allergens 
have the advantage over at the natural allergens that they can be produced as single 
and high purity proteins, on large scale and at reasonable costs 15. 
 
1.2.3 Allergic sensitization and memory responses to allergens 
Primary responses to allergens mainly develop during the first few years after birth 
and the respiratory tract seems to play an important role for sensitization to inhaled 
allergens (e.g., allergens from pollen) 16-18. This primary response is known as 
sensitization (Figure 5a). 
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Mouse models indicate that professional antigen presenting cells (APC) (e.g., 
dendritic cells, B cells and macrophages) present in the airways, capture the 
antigens, process it into small peptides and present them on MHC molecules to T 
cells, and thus induce the primary response 19. In case of B lymphocytes, the antigen 
is captured via specific membrane-bound immunoglobulin and presented directly to 
specific T cells.  As a result of sensitization, specific-IgE antibodies to allergens are 
produced. 
Allergic sensitization (primary response) involves the switch from allergen-specific 
IgM to IgE-producing B cells and leads to the establishment of allergen-specific IgE 
antibody response (memory response) 20. Moreover, after sensitization allergic 
patients contain long-lived  memory T cells. 
 
1.2.4 Allergic reaction is divided into an immediate response and late-phase 
response 
It is well established that acute as well as chronic inflammation is mediated by 
allergen-specific IgE antibodies 21. Allergic inflammation is initiated when an allergen 
crosslinks preformed IgE antibodies bound to the high-affinity Fc receptors (FcεRI) 
on the mast cells. The inflammatory response after IgE-mediated mast-cell activation 
occurs as an immediate reaction (immediate type inflammation). The immediate 
reaction takes place within minutes of allergen provocation and is caused by mast 
cell degranulation, resulting in the release of mediators including histamine, 
serotonin, lipid mediators, proteases, chemokines, and cytokines 22 (Figure 5b).  
This immediate reaction can be followed by a more severe inflammation known as a 
late phase response, which occurs 4-12 hours after antigen exposure and involves 
the recruitment of other effector cells, in particularly Th2 lymphocytes, eosinophils 
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and basophils 20. These late phase reactions are mainly observed in certain allergic 
individuals that suffer from severe and chronic manifestations of allergy (e.g., atopic 
dermatitis and chronic allergic asthma), and are caused by the presentation of 
allergens to T cells leading to activation, proliferation and release of proinflammatory 
cytokines (e.g., IL-1, IL-6, IFN-gamma, TNF-alpha)  23 (Figure 5c). 
The immediate and late phase reaction can be clinically distinguished. The 
immediate reaction is due to the activity of mediators (e.g., histamine, 
prostaglandines) that cause increase in vascular permeability and contraction of 
smooth muscles, whereas the late reaction is associated with a second phase of 
smooth muscle contraction, sustained edema, and cardinal features of allergic 
asthma 24.  
Continuing allergen exposure can stimulate allergen-specific Th2 cells, which 
promote eosinophilia and further IgE production (see 1.2.5), and lead to chronic 
inflammatory response.  
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Figure 5. Induction of allergy by allergens. (a) Allergic sensitization and memory response, 
(b) immediate allergic reaction, (c) late phase allergic reaction 20. 
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1.2.5 Atopic dermatitis 
Atopic dermatitis (AD) is a chronic inflammatory skin disorder affecting about 3-10 % 
of individuals suffering from IgE-mediated allergies 25, 26. The term atopic dermatitis 
was introduced by Hill and Sulzberger 27 due to the association between AD and 
respiratory allergy. The major clinical features of AD are appearance and distribution 
of eczematous lesions, dry skin, papules accompanied by intense pruritus, and 
cutaneous hyperreactivity (Table I) 28, and its histological characteristics are 
spongiosis, hypoerkeratosis, epidermal hyperplasia, and a perivascular infiltrate 
consisting mainly of T cells, macrophages, monocytes and antigen-presenting cells 
(APCs) 28, 29. AD thus resembles many features of a delayed type hypersensitivity.  
AD can be delineated in two forms: extrinsic or allergic form, affecting 70-90 % of AD 
patients, and intrinsic or nonallergic form accounting for 10-30 % of AD cases (Figure 
6). The allergic subtype occurs in the context of sensitization towards environmental 
allergens and is accompanied by elevated serum IgE levels, whereas the nonallergic 
subtype is accompanied by low levels of serum IgE and the absence of detectable 
sensitization 30.  
The observation that patients with T-cell immunodeficiency disorders frequently have 
elevated IgE levels and skin lesions that are indistinguishable from AD suggested a 
immunoregolatory basis in AD (Table II) 28 and today it is known that atopic dermatitis 
is characterized by an initial Th2 cytokines phase that switches to a secondary and 
more chronic Th1 eczematous phase 25.  
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Table I. Diagnostic features of AD 28
 
 
 
Table II. Immunologic features of AD 28
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               Figure 6. The differences between the allergic form of AD and the nonallergic 
               form of AD 25. 
 
 
Several family history and genetic-epidemiologic studies has demonstrated that AD 
has a high level of genetic background 31. However, population studies showed that 
the prevalence of AD has been increasing over the last 20-30 years and thus, 
besides genetic factors environmental risk factors are also proposed in order to 
explain the rapid increase frequency of atopic disorders 32. Several “candidate” genes  
(e.g., IL-4, IL-4R α-chain, IL-13 and CD14 genes) involved in Th1/Th2 cell balance 
have been identified and linked to the AD phenotype 33, 34, 25. Moreover, according to 
the hygienic hypothesis, influences from the environment and exposure to microbial 
pathogens at the early years of life can protect against the development of AD by 
shifting the balance between Th1/Th2 cells  towards a Th1 response 35. Furthermore, 
factors of the modern lifestyle (i.e., the use of antibiotics and increase in adherence 
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to hygienic rules,  what consequently leads to less bacterial contact) might limit Th1 
response and support Th2 predominance in the immune system 36-38. 
Although the basis of allergen-induced acute and late-phase responses is well 
understood, immune mechanisms regulating persistence of local tissue T cell 
activation and inflammation in chronic allergic skin diseases is not well established. 
Taken together, several studies indicate that “long-term allergen, microbial antigen or 
superantigen exposure, Th2 cell stimulation, allergen-specific IgE production, mast 
cell degranulation, eosinophil infiltration, and inflammation amplified by keratinocyte 
injury caused by scratching” 28 are involved and contribute to chronic allergic skin 
inflammation in individuals suffering from AD (Figure 7). 
 
 
           Figure 7. Pathogenesis of atopic dermatitis (AD) 30. 
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The role of IgE in ADT  is an important aspect for the understanding of 
pathomechanisms of chronic allergic skin inflammation. It is assumed that the 
penetration of allergens into the epidermis is facilitated because of the reduced skin 
barrier function in AD patients . It is well established that allergen-recognition by 
IgE antibodies initiates acute allergic manifestation by activation of mast cells and 
basophils . However, the contribution of IgE-mediated versus non-IgE-mediated 
mechanisms to chronic allergic inflammation still remains a matter of controversy. 
39, 40
5
A role of IgE-mediated mechanisms in late-phase reaction has been suggested by 
the fact that IgE-facilitated presentation of allergens leads to strong T cell activation 
(Figure 8) 12, 41, 42. Already in 1990 the importance of cell-bound IgE on epidermal 
Langerhans’ cells for the presentation of allergens in patients with atopic dermatitis 
has been demonstrated 43. Three years later, a study with house dust mite AD 
patients found that allergen presentation is mediated by IgE 44 and a further study 
showed in 1996, that a structural variant of the high affinity receptor for IgE (FcεRI), 
containing FcεRI-α and FcεRI-β chains, is expressed on peripheral blood dendritic 
cells population and that those cells use the FcεRI receptor for IgE-mediated allergen 
presentation 45. Moreover, it has been shown that AD patients benefit from treatment 
with Omalizumab, an anti-human IgE antibody which binds free IgE without cross-
linking IgE that is already bound to FcεRI receptors 46. 
On the other hand, it has been shown that non-IgE-reactive peptides can induce 
allergic inflammation by activation of T-cells and can also induce T cell-dependent 
late phase inflammatory responses 47. These studies demonstrated that allergens 
can activate T cells in an IgE-independent manner and that these allergen-specific T 
cells play a important role in the induction of late-phase symptoms (Figure 8) 12. 
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Figure 8. Mechanisms of allergic inflammation 12.
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1.3 Allergy diagnosis and treatment 
1.3.1 Diagnosis 
The primary method for diagnosis of Type I hypersensitivity is based on the detection 
of serum allergen-specific IgE antibodies levels (in vitro) 48 and on the elicitation of 
immediate symptoms by in vivo provocation testing (e.g., skin testing, nasal 
provocation) 49.  
Skin prick test (SPT) is the most common in vivo method used in clinical practice,  
because of its simplicity, safety and low costs. Moreover SPT is a rather quick 
method, taking 5-15 minutes to develop a skin response, which may persist for 30 
minutes. The characteristic response is a wheal and flare formation. The wheal is 
caused by extravasation of serum from capilaries in the skin and it is accompanied 
by pruritus and large erythematous flare mediated by axon reflex 50. The SPT is 
evaluated by the size of the wheal. A positive SPT indicates that the individual have 
specific-IgE antibodies on mast cells in their skin for the substance tested. 
While immediate-type reactions can easily be identified by patients history, including 
the family history, by measurement of serum IgE levels, and by skin prick testing, the 
evaluation of the role of aeroallergens (e.g., pollens) and food allergy in patients with 
atopic dermatitis presents diagnostic difficulties. However, in recent years the atopy 
patch test (APT) has been established as a useful tool for the diagnosis of food 
allergy and evaluation of eczematous skin reactions because of its high predictive 
capacity for late phase reaction 51, 52. APT is an epicutaneous patch test employing 
allergens known to elicit IgE-mediated reactions. According the European Task Force 
on Atopic Dermatitis (ETFAD), its reactions are read as: -, negative result; ?, only 
erythema, questionable; +, erythema, infiltration; ++, erythema, few papules (up to 3); 
+++, erythema, papules from 4 to < many; ++++, erythema, many or spreading 
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papules; +++++, erythema, vesicles 52. A positive patch response induces 
macroscopic eczema, spongiosis and infiltrate of the cells into the dermis including 
basophils, eosinophils and lymphocytes. Biopsy of patch tests permit to analyse the 
presence of antigen-specific T cells in the skin after the challenge. 
 
1.3.2 Allergen-specific immunotherapy 
Allergen-specific immunotherapy (SIT) represents the only disease-modifying 
approach for IgE-mediated allergies and is based on the repeated administration of 
sensitizing allergen by subcutaneous or sublingual application 11, 53. The allergens 
are usually adjuvant-adsorbed (e.g., aluminum hydroxide). Its mechanisms, which 
are not yet fully understood, include the induction allergen-specific IgG antibodies, 
which inhibit IgE recognition of allergens and thus block allergen-induced allergic 
inflammation and possibly affect immunoregulation 11, 53-55.  
Although SIT is currently recognized as effective treatment for type I allergies, three 
major problems need to be overcome. First, immunotherapy is performed with 
allergen extracts containing mixtures of allergenic and non-allergenic which are 
difficult and in case of many allergen sources impossible to be standardize. Second, 
the administration of allergens can cause IgE-mediated side-effects including 
urticaria, allergic reactions, asthma and anaphylactic shock and third, because of the 
poor quality of the extracts and because of the side-effects therapeutically effective 
doses cannot be achieved 20, 54, 56, 57.  
 
1.3.3 Recombinant allergens and hypoallergenic allergens for treatment 
Although allergen extracts are currently used in allergy therapy, it has been shown 
that when used for vaccination they induce heterogenous immune responses due to 
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the different representation and immunogenicity of the specific allergens in the 
allergen extract 58. Furthermore, the systemic administration of allergens during the 
course of the allergen-specific immunotherapy (SIT) can cause side effects. 
Recombinant allergens have been shown to be useful tools for diagnosis of allergy 
once they maintain comparable immunological features to natural allergen 59. 
Recombinant Bet v 1 has been recently used for vaccination of birch-allergic patients 
and demonstrated to be safe and effective 60. 
In order to overcome IgE-mediated side effects several research groups have 
developed technologies for modifying the IgE reactivity of allergens by recombinant 
DNA technology 20, and hypoallergenic forms of allergens have been developed. 
Recombinant hypoallergenic allergen derivatives represent promising tools for 
diagnosis and therapy of type I allergy. Recombinant hypoallergenic molecules 
provide the advantage to lack IgE reactivity and should not cause immediate type 
symptoms, but they still have the ability to induce allergen-specific protective IgG 
antibody responses. Furthermore they preserve allergen-specific T cell epitopes and 
thus T cell modulatory activities are retained 61.  
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1.4 Birch pollen allergy 
The white birch (Betula verrucosa) is considered as a major pollen-allergen-
producing tree in northern Europe 62. Birch is one of the main causes of Type I 
reactions, such as allergic bronchial asthma and allergic rhinoconjuctivitis, from 
spring to early summer also in middle Europe, North America, Australia and Asia. 
Birch pollen allergy is mainly mediated by one major allergen, Bet v 1, which is 
recognized by 95 % of birch allergic individuals and up to 60 % of such patients react 
exclusively to Bet v 1 63, 64. In addition Bet v 1 is a cross-reactive allergen, which 
contains most of the IgE epitopes present in pollens of trees belonging to the Fagales 
order and in plant-derived food 65, 66. The major birch pollen allergen, Bet v 1, 
comprises 160 amino acid residues 64 and is a 17 kDa protein.  
With the availability of allergen-encoding cDNAs it became possible to express Bet v 
1 in Escherichia coli as recombinant Bet v 1. Cloning, sequence analyses and 
expression of Bet v 1 as a recombinant protein have facilitated the characterization of 
this allergen 64, 67, 68. Several studies showed that recombinant Bet v 1 presents 
molecular and immunological equivalence to natural Bet v 1. It has been 
demonstrated that Bet v 1 is equivalent to natural Bet v 1 in IgE-binding capacity, the 
ability to induce in vitro proliferation of allergen-specific T-cell clones, and the 
biological activity of Bet v 1 has been further demonstrated by skin prick testing and 
by the ability to release histamine from basophils derived from birch pollen-allergic 
individuals. Moreover, the recombinant Bet v 1 has been tested and compared to the 
Bet v 1 wild type in several in vivo studies including skin prick testing and vaccination 
for treatment of birch pollen allergic patients 59, 60, 69-71. In a primate model study, 
recombinant Bet v 1 could induce type I allergy. The study demonstrated that 
monkeys immunized with recombinant Bet v 1 showed positive skin reactions to rBet 
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v 1 and allergen extracts from birch, alder and hazel pollen, which contain Bet v 1 
homologous proteins 70. Further in vivo characterization of potential allergy vaccines 
based on Aluminium hydroxide adsorbed rBet v 1 derivatives in mice showed that 
strong IgG1 and IgG2a/b response was induced by repeated vaccination with rBet v 
1 72. 
Thus Bet v 1 represents a very well-characterized allergen, which could 
demonstrated its efficacy in diagnosis of birch sensitization and for allergen-specific 
immunotherapy. 
 
Birch pollen specific immunotherapy 
On the basis of recombinant-DNA technology it has become possible to modify 
important allergens, such as Bet v 1, and novel treatment strategies for specific 
immunotherapy (SIT) have been proposed. The development of allergy vaccines 
based on recombinant hypoallergenic allergen derivatives has been well advanced 
for birch pollen allergy because the major birch pollen allergen, Bet v 1, represents 
one of the first cloned allergens and because birch pollen allergy represents one of 
the most common forms of respiratory allergy in northern and middle Europe.  
Various different approaches have been developed for the generation of 
hypoallergenic variants of Bet v 1 and three have given promising results in SIT 
studies: fragmentation, oligomerization (rBet v 1 trimer) and chemical denaturation 
(Bet v 1 fold variant) 73-75. The rBet v 1 fragments and rBet v 1 trimer have been 
extensively studied for their reduced allergenic nature in skin prick provocation 
testing in humans before they have been used for vaccination of birch pollen allergic 
patients in immunotherapy studies 73, 74, 76, 77.  
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The rBet v 1 fragments (F1: 1-74 and F2: 75-160), lacked IgE reactivity and exhibit 
strongly reduced or lacking allergenic activity (i.e., basophil activation and induction 
of immediate skin reactions) 73.  
Treatment of birch pollen allergic patients with aluminium hydroxide adsorbates of 
Bet v 1 fragments and Bet v 1 trimer, could induced protective IgG antibodies which 
inhibited allergen-induced release of inflammatory mediators. The reduction of 
cutaneous sensitivity as well as the improvement of symptoms in actively treated 
patients were associated with the development of Bet v 1-specific IgG antibodies 78.  
Although there were basically no IgE-mediated side effects observed in the patients 
who were treated with hypoallergenic Bet v 1 derivatives, late phase side effects 
were observed 79. 
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alternative for MRI procedures in these patients. However, the
predictive value of skin testing could be established only by the
further use of these contrast media and demonstration of an
acceptable tolerance. This has not been pursued in these patients
because of lack of indication for anotherMRI examination as well
as ethical reasons.
These 2 cases of IgE-mediated anaphylaxis to Gd-DOTA
underline the importance of an appropriate allergy assessment,
principally skin tests, to document the drug’s involvement.
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Non–IgE-mediated chronic allergic skin inflam-
mation revealed with rBet v 1 fragments
To the Editor:
Atopic dermatitis (AD) is a chronic inflammatory skin
disorder affecting about 3% to 10% of patients with IgE-
mediated allergies.1 The cardinal features of AD are eczematous
and erythematous skin lesions, which are characterized by
spongiosis, epidermal hyperplasia, and perivascular infiltrates
consisting of T cells, monocytes, macrophages, and antigen-
presenting cells. AD thus resembles many features of delayed-
type hypersensitivity. The symptoms of AD are triggered in
the vast majority of patients with AD by exogenous exposure
to allergens (ie, extrinsic AD), among them food and aeroaller-
gens.2 External application of allergens to the skin by means of
atopy patch tests (APTs) can also be used to elicit the character-
istic eczematous skin lesions in patients with AD for diagnostic
purposes.2
The contribution of IgE-mediated versus non–IgE-mediated
mechanisms to chronic inflammation in patients with AD is a
matter of discussion. Evidence for an important role of IgE-
mediated mechanisms comes from the following findings.
Patients with AD with high levels of IgE express higher levels
of FceRI on monocytes and dendritic cells, and it has been
demonstrated in vitro that IgE-facilitated antigen presentation ac-
tivates allergen-specific T cells more efficiently than allergen
presentation through non–IgE-mediated mechanisms.3 Further-
more, there are reports that certain patients with AD benefit
from treatment with anti-human IgE antibodies.4 On the other
hand, skin manifestations in patients with AD can be improved
by using therapy strategies targeting T cells in a relatively selec-
tive manner.5 In fact, there is also evidence for non–IgE-medi-
ated inflammation in other chronic manifestations of allergy,
such as asthma.6
To study the contribution of IgE-mediated versus non–IgE-
mediated mechanisms in chronic allergic skin inflammation, we
used a purified IgE-reactive major allergen (ie, the birch pollen
allergen Bet v 1 [molecular weight, 17.4 kDa])7 and 2 non–IgE-
reactive hypoallergenic fragments thereof (F1: amino acids 1-
74 [molecular weight, 8 kDa]; F2: amino acids 75-160 [molecular
weight, 9.4 kDa),8 which together comprise the full T-cell epitope
repertoire of the Bet v 1 allergen but lack IgE reactivity and aller-
genic activity (ie, basophil activation and induction of immediate-
type skin reactions) for APTs in patients with AD. We performed
skin prick tests and APTs in 5 patients with AD and birch pollen
allergy, a patient with birch pollen allergy without skin manifes-
tations, an allergic person without birch pollen allergy, and 2 non-
allergic individuals using rBet v 1 or a mix of the 2 rBet v
1 fragments (F1: amino acids 1-74; F2: amino acids 75-160).
The demographic, clinical, and serologic characterization of
the individuals is summarized in Table I. IgE reactivity to rBet v
1 and rBet v 1 fragments (F1 and F2) was tested in a nondenatur-
ing dot-blot assay8 and showed that each of the 6 patients with
birch pollen allergy (patients A-F) contained rBet v 1–specific
IgE (Fig 1 and Table I: 13->100 kUA/L), but none of them con-
tained IgE specific for the Bet v 1 fragments F1 and F2 (Fig
1 and Table I).
Skin prick testing performed on the backs of the patients
confirmed the results of the dot-blot experiments because each of
the 6 patients with birch pollen allergy but none of the individuals
without birch pollen allergy showed immediate-type skin reac-
tivity to rBet v 1 (20 and 40 mg/mL) after 20 minutes (Table I and
Fig E1 in the Online Repository at www.jacionline.org). None of
the 6 patients with birch pollen allergy had immediate-type skin
reactions to equimolar mixes of the rBet v 1 fragments, which
was in agreement with the negative result from the IgE dot-blot
experiment (Table I and see Fig E1). In parallel to skin prick tests,
APTs were performed with aluminum cups (Finn Chambers on
Scanpor, Large, Epitest Ltd Oy, Tuusula, Finland) containing
160mg of rBet v 1 or a mix containing 80mg of each rBet v 1 frag-
ment, as previously described.9 When the APT result was read
and photo documented after 48 hours, we found that rBet v 1 in-
duced a positive eczematous reaction of varying intensity in each
of the patients with birch pollen allergy and AD (subjects A-E)
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but not in the patient with birch pollen allergy without AD (sub-
ject F), the allergic patient without birch pollen allergy (subject
G), and the 2 nonallergic persons (subjects H and I; Table I and
see Fig E1). The non–IgE-reactive rBet v 1 fragment mix induced
an eczematous reaction in 4 of the 5 patients with birch pollen
allergy and AD but not in any of the other persons (subjects
G-I; Table I and see Fig E1). Results of control APTs performed
with Vaseline petroleum jelly (Unilever, London, United King-
dom) alone were negative in each of the 3 patients (data not
shown).
We also studied the occurrence of IgE-bearing cells in the
peripheral blood of the patients using an anti-IgE antibody that
can recognize FceRI-bound IgE antibodies but did not find an
association between the presence of IgE-reactive cells and the
presence or absence of IgE-mediated versus non–IgE-mediated
APT reactions.
Our finding that Bet v 1 fragments containing only T-cell
epitopes but no IgE epitopes could induce chronic allergic skin
inflammation in 4 of the 5 patients with AD indicates that this
reaction is not IgE mediated. The fact that 1 patient with AD
(subject A) had an APT reaction only with IgE-reactive Bet v
1 but not with the Bet v 1 fragments and that subject D had a
stronger reaction with rBet v 1 than with the fragments might be
explained by the dominance of IgE-mediated allergen presenta-
tion mechanisms in these subjects, the loss of a critical T-cell
epitope in the rBet v 1 fragments, or both.
In summary, our experiments provide evidence for an impor-
tant role of non–IgE-mediated reactions in chronic allergen-
induced skin inflammation in patients with AD. Our results also
indicate that recombinant allergen derivatives lacking IgE epi-
topes but containing allergen-derived T-cell epitopes might be
used as test reagents to reveal the contribution of IgE-mediated
versus non–IgE-mediated mechanisms in chronic allergic inflam-
mation. This result might have implications for the selection of
therapy strategies that are either targeting IgE-mediated or purely
T cell–mediated mechanisms. Should larger clinical studies
confirm the results of our pilot studies, such tests might aid the
clinician in optimizing therapy strategies for chronic allergic
inflammation.
Raffaela Campana, MSca
Nadine Mothes, MDa,b
Ingrid Rauter, PhDa
Susanne Vrtala, PhDa
Renate Reininger, PhDc
Margarete Focke-Tejkl, PhDa
Christian Lupinek, MDa
TABLE I. Demographic, serologic, and clinical characterization of individuals
SPT (mm2)
Sex/
Age
(y)
Total
IgE
(kU/L)
IgE CAP (kUA/L) IgE rBet v 1 F11F2 APT
Subject Allergies Symptoms Birch
rBet
v 1
rBet
v 1 F1 F2
20
mg/mL
40
mg/mL
20
mg/mL
40
mg/mL Histamine
rBet
v 1 F11F2
A M/53 b, a, g,
pf, npf,
mo, mi
AD, RC,
AS, OAS
860 15.7 14.6 1 2 2 100 132 2 2 16.6 111 2
B M/41 b, pf RC, AD 69.3 27.4 27.1 1 2 2 56 121 2 2 8 11 111
C M/45 b, a, g,
pf, mi
RC, AD, OAS 114 25.6 20.2 1 2 2 156 210 2 2 72 1 1
D M/54 b, a, g,
pf, npf,
mo, mi, w
RC, AD >5000 >100 >100 1 2 2 90 81 2 2 64 1111 11
E M/37 b, a,
g, w
RC, AD, AS 747 58.3 13 1 2 2 81 90 2 2 42 111 111
F F/44 b, a, g RC, AS, OAS 466 57.5 60.5 1 2 2 110 132 2 2 30 2 2
G F/36 a, g RC 25.7 <0.35 <0.35 2 2 2 2 2 2 2 15.5 2 2
H F/26 No 2 <2.00 <0.35 <0.35 2 2 2 2 2 2 2 11.2 2 2
I F/32 No 2 2.65 <0.35 <0.35 2 2 2 2 2 2 2 10.6 2 2
Subjects were characterized by sex, age, and clinical diagnosis of allergies. IgE reactivity for rBet v 1 and rBet v 1 fragments (F1 and F2) was analyzed in
a dot-blot assay and by means of IgE CAP.
M, Male; F, female; SPT, skin prick test; b, birch; a, animals; g, grass; pf, plant food; npf, non–plant-derived food; mo, molds; mi, mites; w, weeds; RC, rhinoconjunctivitis;
AS, asthma; OAS, oral allergy syndrome.
FIG 1. IgE reactivity. Dot-blotted antigens (rBet v 1, human serum albumin
[HSA], the rBet v 1 fragments F1 and F2, BSA, and an equimolar mix of
rBet v 1 fragments [F11F2]) were exposed to sera from the individuals
listed in Table I (A-I) or buffer alone (0). Bound IgE was detected and visu-
alized by means of autoradiography.
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Nasal nitric oxide as a noninvasive marker in
the antibiotic treatment of acute bacterial
sinusitis
To the Editor:
Acute bacterial sinusitis (ABS) is associated with inflammation
of the sinuses. The resulting infection is from a bacterial growth in
the fluid that accumulates when other conditions cause sinus
blockage. Use of 2 major factors or 1 major and 2 minor factors
for the clinical diagnosis of ABS is paramount.1 Sampling with
rhinoscopy from the maxillary sinuses for bacterial confirmation
is the gold standard for confirming ABS,2 but it is invasive and
impractical at times.
Nitric oxide (NO) is a known noninvasive marker of inflam-
mation that can be used to quickly measure airway inflammation.
Sinus NO is found in the thousands range of parts per billion,
which decreases to approximately half in the nose and by a factor
of 100 in the lungs. NO is a product of constitutive and inducible
NO synthase. Constitutive NO is protective against infection in
respiratory airways. Although inducible NO levels are increased
with inflammation in the lower airways, obstruction of the sinus
ostia in sinusitis reduces the nasal NO level.3,4
We proposed to measure nasal NO levels in patients with ABS
before and after antibiotic therapy. All patients were seen acutely
for signs and symptoms of ABS with at least 3 major diagnostic
factors. These patients presented to our allergy practice unsched-
uled and were not actively recruited. The mean age for the 15
patients (female patients, n 5 12) was 33 years (range, 11-55
years). Seven of 15 patients have a history of chronic rhinosi-
nusitis (CRS) defined by duration of their sinus disease, and 12
patients were atopic on the basis of history and skin prick test
responses.
NO levels were measured online with an NO analyzer (NIOX,
Aerocrine, Sweden) equipped with nasal NO software. Nasal NO
levels were measured by means of chemiluminescence from a na-
ris by using a nasal olive at a constant flow with the contralateral
side open, as per American Thoracic Society guidelines.3 The
patient was instructed to inhale through the mouth to total lung
capacity and breath hold for 20 seconds while humming.5,6
Both sides were measured to compare differences from either
side.
A computed tomographic (CT) scan of the sinuses was
performed after the initial NOmeasurements and before initiation
of antibiotic therapy. For bacterial coverage of their ABS, patients
received, depending on their age and drug allergy history, oral
amoxicillin-clavulanate, cephalosporin, or a quinolone for 5 to 14
days according to the prescribed course of therapy. NO levels
were measured 2 weeks after the start of antibiotic therapy in the
samemanner. Patients were examined by the physician before and
after treatment to confirm the diagnosis and response to therapy.
Nasal medications that were being used before the ABS were
continued, and no other new medications were initiated in
addition to the antibiotic regimen.
The mean NO level was 275 6 178 ppb before antibiotics
and increased to 1126 6 395 ppb after antibiotic treatment
(Fig 1). In patients without CRS, the mean change of improve-
ment in NO level was 11114 ppb after antibiotic therapy
(mean postantibiotic NO value, 1400 ppb), although in patients
with CRS, the mean change of improvement in NO was
1550 ppb after antibiotic therapy (mean postantibiotic NO
value, 811 ppb).
Ten of the 15 patients studied had lower levels of NO in the
naris, which is consistent with their unilateral ABS symptoms and
CT scan findings. The remaining 5 patients with bilateral ABS
had bilateral NO levels decreased before treatment and later
confirmed by means of CT scans. There was no significant
difference between the naris in the bilateral ABS group. Nasal NO
FIG 1. Pretreatment (Pre-tx) to posttreatment (Post-tx) NO levels in all
subjects, with black bars denoting the median. *P < .001.
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FIG E1. Immediate- and delayed-type skin reactions to rBet v 1 and rBet v 1 fragments. Skin prick tests (SPT)
and APTs were performed with rBet v 1 (1 and 2) and rBet v 1 fragments (3 and 4) in 5 patients with AD (A-E)
and in 1 individual with rhinoconjunctivitis (F) with birch pollen allergy, 1 allergic patient without birch
pollen allergy (G), and 2 nonallergic individuals (H and I). Skin prick tests were performed with 2 antigen
concentrations of 20 mg/mL (1 and 3) or 40 mg/mL (2 and 4). APTs were performed with 160 mg of rBet v
1 or with a mix containing 80 mg of each rBet v 1 fragment (F11F2).
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Abstract 
 
Background: In contrast to other recombinant hypoallergenic allergen derivatives which 
showed reduced IgE reactivity, a recombinant trimer of the major birch pollen allergen Bet v 
1 showed reduced allergenic activity despite preserved IgE reactivity.  
Methods: We studied rBet v 1 trimer by SDS-PAGE, mass spectrometry, circular dichroism 
and gel filtration. Furthermore we investigated IgE and IgG reactivity of the rBet v 1 trimer in 
solid and liquid phase assays and compared its allergenic activity with that of rBet v 1 
wildtype using basophil activation assays.  
Results: In solid phase immunoassays rBet v 1 trimer exhibited even stronger IgE reactivity 
than the rBet v 1 monomer, whereas both proteins were equally well recognized by Bet v 1-
specific IgG antibody probes. In fluid phase IgE experiments rBet v 1 trimer inhibited IgE 
reactivity to rBet v 1 wildtype but showed a more than 10-fold reduced allergenic activity 
compared to the rBet v 1 monomer. By analytical gel filtration it was demonstrated that, 
despite its monomeric appearance in SDS-PAGE  the trimer occurred in fluid phase in the 
form of defined high molecular weight (>600 kDa) aggregates whereas rBet v 1 wildtype 
strictly appeared as monomeric protein. 
Conclusion: The results indicate that the hypoallergenic nature of the rBet v 1 trimer is due to 
formation of defined high molecular weight aggregates which may be responsible for an 
altered presentation of IgE epitopes in a form with reduced capacity to crosslink effector-cell 
bound IgE. 
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Introduction 
Allergen-specific immunotherapy (SIT) represents the only antigen-specific and disease-
modifying treatment approach for IgE-mediated allergy (1-3). However, the administration of 
allergens in the course of immunotherapy can induce local and systemic inflammation and in 
the worst case severe systemic and life-threatening side effects (4, 5).  
In order to overcome the most severe type of side effects, i.e., systemic life-threatening 
anaphylaxis, which is caused by IgE-mediated mast cell and basophil degranulation, 
technologies have been developed for the reduction of IgE reactivity of allergy vaccines (6). 
Already forty years ago David Marsh and colleagues developed chemically modified allergen 
extracts which exhibited reduced IgE reactivity but at the same time could induce allergen-
specific IgG antibodies and retained allergen-specific T cell epitopes (7). These chemically 
modified allergen preparations have been designated “allergoids” and until today these or 
similar preparations are the active ingredients of many routinely used allergy vaccines. Based 
on allergen-encoding sequences, several research groups have started to develop 
hypoallergenic allergen derivatives based on recombinant DNA technology (6, 8).  
All hypoallergenic allergen derivatives exhibited reduced IgE reactivity and the reduced 
allergenic activity thus resulted from this reduction of IgE reactivity.  
One exception to this rule is a recombinant trimer of the major birch pollen allergen, Bet v 1, 
which has been obtained by the expression of three copies of the cDNA coding for Bet v 1 
(9). The recombinant Bet v 1 trimer exhibited a strongly reduced ability to induce IgE-
mediated basophil activation, showed reduced induction of immediate type skin reactions and 
nasal reactivity and has been used in high doses for immunotherapy of birch pollen allergic 
patients (10, 11).  
Surprisingly, despite its reduced allergenic activity, rBet v 1 trimer was found to exhibit IgE 
reactivity compared to the rBet v 1 wildtype allergen (9).  
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In this study we conducted a series of protein-chemical, structural and immunological 
experiments to re-investigate the unusual reduction of allergenic reactivity of  the rBet v 1 
trimer.   
 
Methods 
Plasmids, patients’ sera and antibodies 
The plasmids expressing rBet v 1 and rBet v 1 trimer are described (12, 9).  
Birch pollen allergic patients (n = 11) were characterized by case history and skin prick 
testing. Specific IgE levels to birch pollen extract and rBet v 1 were determined by immuno 
CAP measurements (Phadia, Uppsala, Sweden) as described (13). Control serum was taken 
from a non-allergic volunteer with no history of birch pollen allergy, lack of skin reactivity 
and birch pollen-specific IgE. IgE reactivity testing and basophil activation experiments were 
done with serum samples and cells obtained from the same birch pollen allergic patients. 
Specific polyclonal rabbit Abs against the purified rBet v 1, rBet v 1 trimer and against two 
rBet v 1 fragments (F1 and F2) as described (9, 14). Monoclonal mouse IgG Abs against 
peptide 2 (mAb#2) comprising amino acids 30-59 of Bet v 1 and against peptide 6 (mAb#12) 
comprising amino acids 74-104 of Bet v 1 were obtained by immunization of mice using 
KLH-coupled synthetic peptides (peptide 2: LFPKVAPQAISSVENIEGNGGPPTIKKISF; 
peptide 6: EDVHTNFKYNYSVIEGGPIGDTLEKISNEIK). Monoclonal Bet v 1-specific 
antibody, Bip 1, is described (15). The mouse monoclonal antibody 4A6 was raised against 
purified recombinant birch pollen profilin (16). Anti-IgE mAb E-124.2.8 was obtained from 
Immunotech (Marseille, France). Chimeric Bip 1, an IgE monoclonal antibody with 
specificity for Bet v 1, was generated and purified as described (17).  
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Expression and purification of recombinant allergens 
Recombinant Bet v 1 (batch # 21) and grass pollen allergen, Phl p 5 (batch # 04), were 
purchased from Biomay (Vienna, Austria). 
Recombinant Bet v 1 trimer was expressed in E.coli BL 21 (DE3) (Stratagene, La Jolla, CA, 
USA) (Supplementary information 1).  
 
SDS-PAGE and immunoblotting 
Purified rBet v 1 and rBet v 1 trimer (5 μg protein/slot) were separated by 12.5 % SDS-PAGE 
in the presence or absence of 2-mercaptoethanol (18).  Proteins were visualized by staining 
with Coomassie Brilliant Blue. 
IgG and IgE-binding capacity of purified rBet v 1 and rBet v 1 trimer were also tested by 
Western blotting (Supplementary information 2).  
 
Mass spectrometry and Circular dichroism 
Mass spectrometry was done as described (Supplementary Information 3).  
Circular dichroism (CD) measurements were done using a JASCO (Tokyo, Japan) J-810 
spectropolarimeter. The CD spectra of purified rBet v 1 and Bet v 1 trimer were measured at 
room temperature at concentration of 0.1 mg/ml using a rectangular quartz cuvette with 0.2-
cm path length. Far ultraviolet (UV) spectra were recorded in the wavelength ranges between 
190 and 260 nm with a resolution of 0.5 nm at a scan speed of 50 nm/min. Data of three 
measurements were averaged. The final spectra were baseline-corrected and results were 
expressed as the mean residue ellipticity (Θ) at a given wavelength. The secondary structure 
content of rBet v 1 and rBet v 1 trimer was calculated using the secondary structure estimation 
program CDSSTR (19). 
 
                                                                            Campana et al.                          
IgE and IgG reactivity of rBet v 1 and rBet v 1 trimer 
Purified rBet v 1 and rBet v 1 trimer were tested for IgE reactivity in dot blot assays and by 
ELISA (Supplementary information 4).   
 
Basophil activation by flow cytometry: CD203c assay 
Peripheral blood samples were obtained from ten out of the eleven birch pollen allergic 
patients used for IgE reactivity testing. Blood was collected in heparinized tubes after 
informed consent was given. Blood aliquots (100 µl) were incubated (unique) with serial 
dilutions of rBet v1 (0.05 pM to 0.5 nM), rBet v1 trimer (0.05 pM to 0.5 nM) or anti-IgE mAb 
E-124.2.8 (Immunotech, Marseille, France ) (1µg/ml), or PBS for 15 minutes at 37 °C, and 
CD203C expression was measured (20). 
 
Gel Filtration 
For gel filtration 300 μl aliquots of the proteins (rBet v 1 trimer: c=1.9mg/ml; rBet v 1: 
c=1mg/ml) were loaded onto a Superdex 200 10/300 GL column (GE Healthcare, Uppsala, 
Sweden) at 4ºC, equilibrated with 10 mM phosphate buffer pH 7.5 containing 150 mM NaCl. 
The flow rate was 0.5 ml/min and fractions of 0.5 ml were collected. The molecular masses 
(MM) of the fractions were calculated based on the gel filtration of standard proteins 
performed under identical conditions (BioRad: Thyroglobulin, 670 kDa; Bovine gamma 
globulin, 158 kDa; Chicken ovalbumin, 44 kDa; Equine myoglobin, 17 kDa; vitamin B12, 
1.35 kDa; vitamin B12). The peak fractions were concentrated using a CENTRIVAP 
(Labconco Corp., Kansas City, MO, USA) vacuum concentrator without heating. 
Concentrated fractions were subjected to immunological investigations or for 5 days at 4ºC 
and reapplied to gelfiltration with the Superdex 200 10/300 GL column to check the stability 
of elution profile. 
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Rat basophil leukemia cells mediator-release assay 
Rat basophil leukemia cells (RBL-2H3) transfected with the human high affinity IgE receptor 
FcεRI (clone RBL-703/21), kindly provided by S. Viehts (21), were loaded with different 
dilutions of the chimeric Bip 1 antibody (10 μg/ml, 1 μg/ml, 100 ng/ml, 10 ng/ml, 1 ng/ml, 
100 pg/ml, 10 pg/ml and 1 pg/ml), washed 3 times with Tyrode’s buffer (Sigma-Aldrich, 
Vienna, Austria) and then exposed to different concentrations (10 μg/ml, 1 μg/ml, 100 ng/ml, 
10 ng/ml, 1 ng/ml, 100 pg/ml) of rBet v 1, rBet v 1 trimer or a non-cross-reactive grass pollen 
allergen, Phl p 5. The release of  β-hexosaminidase was measured as described (22).  
 
Results 
Expression, purification and physicochemical properties of rBet v 1 and rBet v 1 trimer  
The Coomassie blue-stained SDS-PAGE shows that recombinant Bet v 1 trimer appears in 
SDS-PAGE under reducing as well as under non-reducing conditions mainly as a monomeric 
protein of approximately 52 kDa (Figs. 1A, +Met, -Met). Few very weak bands of lower and 
higher molecular weight than 52 kDa were observed in the recombinant trimer preparation. 
Recombinant Bet v 1 migrated as a single protein band at approximately 17 kDa (Fig. 1A, 
left).  
MALDI-ToF analysis of purified rBet v 1 resulted in two prominant mass peaks of 17370.9 
Da, corresponding to the monomeric form without methionine and another of 8654.9 Da, 
corresponding to the double charged molecule (Supplementary figure 1). MALDI-ToF 
analysis of rBet v 1 trimer resulted in a peak of 53068.1 Da. The mass determined by mass 
spectrometry for the trimer was slightly greater than the predicted mass which could be due to 
binding of urea (+ 43 Da), Na (+ 22 Da), K (+ 38 Da), oxidation of methionine (131 Da) and 
combinations of these modification (Supplementary figure 1). A peak corresponding to half of 
the molecule (double charged 26633.3 Da) was also observed. For measurement of the rBet v 
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1 trimer a higher laser intensity than for rBet v 1 had to be used (rBet v 1 trimer: 69%; rBet v 
1: 52%), which resulted in a prominent matrix peak between 6000 to 14000 Da. 
The Bet v 1 CD spectrum exhibits a shape typical for a mixed α/β fold, with a broad minimum 
at 215 nm and a maximum at 195 nm (Fig. 1B). In contrast, the CD spectrum of Bet v 1 
trimer displays a shift of the minimum as well as the maximum towards shorter wavelengths, 
indicating a higher content of random-coil elements contributing to the overall structure (Fig. 
1B). For rBet v 1 an α-helix content of 27 % and a β-sheet content of 30 % were calculated 
and for the trimer the values were 16 % and 28 %, respectively, indicating a loss of mainly α-
helical secondary structure elements in the trimer as compared with the monomer structure. 
 
Recombinant Bet v 1 trimer shows even stronger IgE reactivity than rBet v 1  
Figure 2A shows the IgE reactivity from 11 birch pollen allergic individuals, one non-allergic 
person and buffer to rBet v 1 and rBet v 1 trimer. Each of the birch allergic patients sera 
displayed IgE reactivity to rBet v 1 trimer and to rBet v 1 (Fig. 2A, A-K).  
Interestingly, rBet v 1 trimer showed always more intensive IgE reactivity than rBet v 1. No 
IgE reactivity was observed with serum from the non-allergic individual and with the buffer 
control (Fig. 2A, L and 0). Similar results were obtained in a Western blot assay. Each of the 
allergic patients showed stronger IgE reactivity to rBet v 1 trimer than to rBet v 1 (data not 
shown).  
Also by ELISA we found that rBet v 1 trimer exhibited a much stronger IgE reactivity than 
rBet v 1 (Fig. 2B).  
 
Similar recognition of solid-phase-bound rBet v 1 trimer and rBet v 1 by IgG antibodies  
We then tested the binding of  polyclonal rabbit antisera which had been raised against 
purified rBet v 1, rBet v 1 trimer and against two rBet v 1 fragments (F1 and F2) as well as 
mouse monoclonal IgG antibodies raised against peptide 2 (mAb#2) comprising amino acids 
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30-59 of Bet v 1 and against peptide 6 (mAb#12) comprising amino acids 75-104 of Bet v 1 
or the Bip 1 mouse monoclonal antibody raised against natural, pollen-derived Bet v 1 to rBet 
v 1 and rBet v 1 trimer. Unlike allergic patients IgE, each of the IgG antibodies reacted 
equally well with the two proteins at each of the tested dilutions (Figs. 2C, A-G).    
 
rBet v 1 trimer and rBet v 1 inhibit allergic patients IgE reactivity to each other equally 
well in fluid phase 
Next we investigated the extent to which each of the two proteins can inhibit IgE reactivity to 
the other protein, by IgE ELISA competition assays. Sera from the very same 11 Bet v 1 
allergic patients which had been tested for IgE reactivity before, were pre-incubated with 
different concentrations of either rBet v 1 trimer, rBet v 1 or BSA as control protein and then 
allowed to bind to ELISA plate-coupled rBet v 1 trimer or rBet v 1 (Fig. 2D). We found that 
rBet v 1 trimer and rBet v 1 inhibited patients IgE reactivity to rBet v 1 in a comparable 
manner at each of the four inhibitor concentrations (5 ng - 5 μg/ml) (Fig. 2D, left). Similar 
results were obtained when rBet v 1 trimer and rBet v 1 were tested for the inhibition of 
allergic patients IgE binding to rBet v 1 trimer (Fig. 2D, right). 
 
Reduced allergenic activity of rBet v 1-trimer compared to rBet v 1 as determined by 
CD203c up-regulation on patients´ basophils  
Heparinized blood samples from ten of the eleven allergic patients tested for IgE reactivity 
were incubated with different concentrations of rBet v 1 trimer or rBet v 1 (Fig. 3). For these 
experiments we used equimolar amounts of the proteins so that the amount of rBet v 1 
equivalents in the rBet v 1 trimer preparation were approximately three-fold as high as in the 
rBet v 1 samples. Nevertheless, we found that rBet v 1 trimer exhibited a 10- to 100-fold 
reduced allergenic activity compared to rBet v 1 in almost each of the tested patients (Fig. 3).    
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In solution  rBet v 1 trimer occurs in the form of defined aggregates whereas rBet v 1 is 
monomeric 
Analytical gel filtration showed that the rBet v 1 trimer appeared in three distinct peaks in 
liquid phase. The first and most prominant peak eluted at 7.5ml, corresponding to 
approximately the 20-fold mass (i.e., 800-1000 kDa) of the protein. Thyroglobulin which has 
a molecular weight of 670 kDa eluted at 9.25 ml. A second peak of about half of the size, 
appeared at 10.5 ml corresponding to approximately the 10-fold mass of the trimer (i.e., 500 
kDa) and a third small peak eluted at 12.5 ml corresponding to approximately the 2-fold of 
the trimer molecule (Fig. 4A). When the peaks of the trimer were re-run on a gel filtration 
column after storage at 4oC (Fig. 4B) a similar profile was obtained. Most of the trimer 
appeared as high molecular weight aggregated form with a more than 10-fold molecular mass 
(Fig. 4B). When rBet v 1 was applied to analytical gel filtration, the protein eluted exclusively 
as a single peak at 16.9 ml corresponding to the monomeric form of the protein with a 
molecular mass of 17 kDa (Fig. 4C). 
 
rBet v 1 trimer but not rBet v 1 induces β-hexosaminidase release from basophils loaded 
with monoclonal Bet v 1-specific IgE 
RBL cells which had been transfected with human FcεRI were loaded with a rBet v 1-specific 
human monoclonal IgE antibody and subsequently exposed to different concentrations of rBet 
v 1 and rBet v 1 trimer. rBet v 1 trimer induced a dose-dependent release of β-
hexosaminidase, starting at a concentration of 10 ng/ml with 14.86 % of  total release and 
increased to 69.22 % when the RBL were exposed to the highest concentration of allergen 
tested (10 μg/ml) (Table 1). rBet v 1 failed to induce mediator release in sensitized RBL cells 
due to its monomeric nature (Table 1).  
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Discussion 
In the last 10 years an increasing number recombinant or synthetic hypoallergenic allergen-
derivatives has been engineered which are also characterized by a reduced reactivity with IgE 
antibodies (6, 8). Here we have investigated an unusual hypoallergenic allergen derivative, a 
recombinant trimeric form of the major birch pollen allergen, Bet v 1, which despite retained 
IgE reactivity was shown to exhibit reduced allergenic activity (9, 11).  
Using SDS-PAGE performed under reducing and non-reducing conditions as well as mass 
spectrometry, rBet v 1 trimer appeared as a monomeric, soluble protein with a molecular 
weight corresponding to the molecular weight which was predicted based on its sequence. 
The comparison of the fold of the rBet v 1 trimer with that of the Bet v 1 monomer 
demonstrated that the trimer exhibited a similar fold as rBet v 1 with a reduction of alpha 
helical elements in its secondary structure. It has been shown for other hypoallergenic Bet v 1 
derivatives such as recombinant fragments (23), a folding variant of Bet v 1 obtained by 
exposing rBet v 1 to NaOH (24) and for certain isoforms/mutants (25-27) that a loss of fold or 
altered fold is associated with reduced IgE reactivity. However, despite the altered fold, rBet v 
1 trimer reacted with patients IgE antibodies as well as with several different IgG antibody 
probes recognizing sequential or conformational epitopes of Bet v 1 or certain Bet v 1 
portions in a similar manner as rBet v 1. The IgE reactivity of rBet v 1 trimer was even higher 
than that of rBet v 1 wildtype in two different solid phase assays and comparable in fluid 
phase competition assays. The higher IgE reactivity in the solid phase assays may be 
explained by the fact that the immobilization procedure occupies more IgE epitopes on a 
small molecule (i.e., Bet v 1) as compared to the bigger trimer. Yet, both molecules showed 
identical IgE reactivity in fluid phase inhibition assays using different concentrations of each 
molecule for the inhibition of IgE reactivity.  
Despite the fact that rBet v 1 trimer and rBet v 1 wildtype inhibited IgE binding to each other 
in a similar manner, we found that the trimeric form exhibited an a ten- to hundredfold 
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reduction of allergenic activity when exposed to basophils from allergic patients. This 
surprising reduction of allergenic activity cannot be explained by a variability of protein 
concentrations in the experiments because extra care was taken to determine the 
concentrations of trimer and rBet v 1 before each of the critical experiments in parallel and all 
experiments were performed using protein concentrations calculated to contain the same 
number of Bet v 1 molecules for IgE binding assays. For the basophil activation studies we 
even used equimolar amounts of trimer and rBet v 1. Thus the trimer preparation contained a 
threefold excess of Bet v 1 molecules compared to rBet v 1 but still the allergenic activity was 
10-100 fold reduced. Furthermore, serum samples and cells were obtained from the very same 
patients for IgE reactivity testing and for the assessment of allergenic activity to assure that 
the results are not caused by a variability regarding patients materials.  
Based on the first set of experiments we therefore had to conclude that the trimer despite 
maintained IgE reactivity exhibited a strongly reduced allergenic activity, presumably due to 
a less efficient cross-linking of basophil-bound IgE compared to the rBet v 1 wildtype. 
Gel filtration/size exclusion experiments showed that the trimer despite its overall monomeric 
appearance in stained gels, occurred in the form of high molecular weight aggregates in 
solution. The majority of these aggregates resembled a peak of approximately the 20-fold 
mass of the trimer and two smaller fractions corresponding to the 10- and 2-fold mass, which 
even after collection and storage at 4°C remained stable. By contrast, rBet v 1 wildtype 
behaved strictly as monomeric protein in the gel filtration experiments. The monomeric 
appearance of rBet v 1 wildtype is in contrast to earlier published work which claimed that 
Bet v 1 and allergens in general exhibit their allergenic activity (i.e., cross-linking of effector 
cellbound IgE) due to oligomerization (28). We therefore performed another type of 
experiment in which we loaded rat basophil leukemia cells which had been transfected with 
the human FcεRI with Bet v 1-specific human monoclonal IgE antibodies and subsequently 
exposed them to the trimer and rBet v 1 wildtype allergen. The results of these experiments 
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confirmed that rBet v 1 wildtype behaves as monomeric protein in solution because it did not 
cross-link monoclonal IgE whereas the trimer induced cross-linking, albeit at relatively high 
concentrations which is in accordance with its low allergenic activity and in good agreement 
with earlier data which had been obtained with purified human mast cells (29).  
Based on the obtained results we propose the following explanation for the hypoallergenic 
nature of the rBet v 1 trimer as shown in Figure 5. According to structural studies and site 
directed mutagenesis experiments there is evidence that Bet v 1 contains a major IgE epitope-
containing region (26, 27) which is obviously accessible to IgE antibodies on the monomeric 
as well as on the trimeric form of Bet v 1 although the latter forms high molecular weight 
aggregates. Since Bet v 1 does not contain cysteins we assume that the formation of 
aggregates is due to an association of hydrophobic portions of the trimer within the aggregate 
leaving hydrophilic, IgE-reactive areas available outside. In this scenario both, the aggregated 
trimer and the monomers can bind a comparable number of IgE antibodies in solution (Fig. 
5A-B), an assumption which is supported by the results of the IgE inhibition experiments. 
However, when the molecules are exposed to cell-bound IgE antibodies only the monomeric 
Bet v 1 molecules seem to be able to cause efficient cross-linking of IgE antibodies due to the 
fact that each of these molecules can present the IgE epitope containing areas well to cell-
bound IgE (Fig. 5C-D). For the aggregated trimer we assume that only a certain percentage of 
the IgE epitopes which are available on the surface of this molecule assume a spatial 
arrangement which allows cross-linking of cell-bound IgE whereas a considerable number of 
the IgE epitopes is less well accessible to the cell-bound IgE antibodies (Fig. 5D).  
Our hypothesis is in agreement with data obtained for other allergens indicating that the 
spatial arrangement of IgE epitopes on a given protein may have an important influence on 
the allergenic activity of this protein in terms of its capacity to induce allergic inflammation 
via cross-link of effector cell-bound IgE (30-32). It may thus be possible to convert highly 
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allergenic proteins into low allergenic proteins for therapeutic purposes by a hitherto 
unknown mechanism, i.e., a reorientation of IgE epitopes. 
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Figure and Tables  
 
Figure 1. Physical-chemical characterization of rBet v 1 and rBet v 1 trimer by SDS-PAGE. 
(A) Comparison of purified recombinant Bet v 1 and rBet v 1 trimer (left). rBet v 1 trimer run 
in the presence (+Met) or absence (-Met) of 2-mercaptoethanol. M, molecular mass markers 
(kDa). (B) Circular dichroism analysis of rBet v 1 and rBet v 1 trimer. The mean residue 
ellipticities (y-axes) are shown for rBet v 1 trimer and for rBet v 1 at different wavelengths (x-
axes). 
 
Figure 2. IgE and IgG reactivity of rBet v 1 and rBet v 1 trimer. (A) IgE reactivity of dot-
blotted rBet v 1 and rBet v 1 trimer. IgE reactivity of nitrocellulose-dotted rBet v 1, rBet v 1 
trimer, human serum albumin (HSA) and bovine serum albumin (BSA) after incubation with 
sera from 11 birch pollen allergic patients (A-K), serum from one non-allergic person (L) or 
buffer (0). (B) IgE reactivity of ELISA plate-bound rBet v 1 and rBet v 1 trimer. IgE 
reactivities (OD values) of sera from 11 birch pollen allergic patients (A-K) to rBet v 1 and 
rBet v 1 trimer. (C) Reactivity of rBet v 1 and rBet v 1 trimer with specific IgG antibodies. 
IgG reactivities (y-axes: OD values) of different dilutions (x-axes) of  rabbit anti-rBet v 1 (a), 
anti-F1 (b), anti-F2 (c), anti-Trimer (d), mAb#2 (e), mAb#12 (f) or mAb Bip 1 (g) with rBet v 
1 (●), rBet v 1 trimer (■) and BSA (▲). (D) Inhibition of IgE binding to solid phase-bound 
rBet v 1 or rBet v 1 trimer by rBet v 1 or Bet v 1 trimer in fluid phase. The percentages of 
inhibition of IgE binding to solid phase-bound rBet v 1 (left) and rBet v 1 trimer (right) are 
shown on the (y-axes) after pre-incubation of sera from 11 birch pollen allergic patients with 
different concentrations (x-axes) of rBet v 1 or rBet v 1 trimer. Results are displayed as box 
plots with median values in the boxes, standard deviations and extremes (asterisks) and 
outliers (circle).   
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Figure 3. In vitro allergenic activity of rBet v 1 and rBet v 1 trimer as determined by CD203c 
up-regulation on allergic patients basophils. Blood samples from birch pollen allergic 
individuals were exposed to different concentrations of rBet v 1 (black bars) and rBet v 1 
trimer (open bars), anti-IgE or buffer (0) (x-axes). The upregulation of CD203c expression is 
displayed in the form of stimulation indices (SI) (y-axis) for each of the 10 patients (A-J).  
 
Figure 4. Aggregate formation of rBet v 1 trimer in solution. (A) Demonstration by gel 
filtration that rBet v 1 trimer occurs in fluid phase in the form of defined aggregates. Profile 
of rBet v 1 trimer eluted from a gel filtration column (x-axis: Elution volumes in ml; y-axis: 
absorbance at 280nm). Arrows indicate peaks of a protein standard consisting of 
thyroglobulin 670 kDa (9.25ml), bovine gamma globulin 158 kDa (12.35ml), chicken 
ovalbumin 44 kDa (15.17ml), equine myoglobin 17 kDa (17.23ml), Vitamin B 12 1.35 kDa 
(20.55ml). (B) Gel filtration re-run of the trimer peaks (blue: sample 14, ~ 8ml; pink: samples 
16-17, ~ 9-9.5ml; green: samples 24-26, ~ 12-13.5ml) after 5 days of incubation at 4 ºC. (C) 
Elution profile of rBet v 1 (16.9 ml). 
 
Table 1. Induction of ß-hexosaminidase release. RBL cells that had been transfected with 
human FcεRI were sensitized with different concentrations of human IgE mAb α Bet v 1 (Bip 
1) and then stimulated with increasing concentrations of rBet v 1 and rBet v 1 trimer. The 
release of ß-hexosaminidase is shown as percentage of the total ß-hexosaminidase contents of 
the cells.  
 
Figure 5. Model for the hypoallergenic behavior of rBet v 1 trimer. Bet v 1 molecules in their 
monomeric form (A: rBet v 1) or as aggregated trimer (B: Trimer) can bind a comparable 
number of IgE antibodies in solution. However, monomeric rBet v 1 molecules may be more 
efficient in cross-linking of effector cell-bound IgE (C) than the aggregated trimer (D). IgE 
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epitopes on monomeric forms of Bet v 1 can be well accessed by effector cell-bound IgE 
whereas only a certain portion of the IgE epitopes on the aggregated trimers comes into an 
optimal position for cross-linking of effector cell-bound IgE. 
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Table 1. Induction of ß-hexosaminidase release.  
 
 
 
  rBet v 1 Trimer 
Bip 1dilution 10 µg/ml 1 µg/ml 100 ng/ml10 ng/ml10 µg/ml1 µg/ml100 ng/ml10 ng/ml
10 µg/ml 4.0 2.8 2.1 1.4 69.2 65.3 14.9 0.3 
1 µg/ml 1.8 1.5 1.2 0.8 69.1 58.5 9.6 0.1 
100 ng/ml 0.4 0.3 0.3 0.3 50 41.8 1.8 0.5 
 
 
 
Supplementary Figure 1: Mass spectrometric analysis of rBet v 1 and rBet v 1 trimer. 
the mass/charge ratios are shown on the x-axes, and the signal intensities are displayed
on the y-axis as absolute value in the investigated mass range.
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Supplementary Information 1: Expression and purification of rBet v 1 trimer 
Batch fermentation of  E.coli BL 21 (DE3)/pET-17b-Bet v 1 trimer was carried out in a 10 L 
Bioflow 3000 fermenter (New Brunswick Scientific, New Jersey, USA) in LB medium with 
the addition of 0.05 % (v/v) glycerol, 0.25 % (w/v) MgSO4 . 7 H2O, and 0.18 % Na2HPO4 . 2 
H2O for 8 h at 37°C, until a cell density (OD600nm) of  7 was reached. As soon as OD600nm  
reached 1, expression of Bet v 1 trimer and formation of inclusion bodies was induced by 
adding isopropyl-β-thiogalactopyranoside (IPTG) (Calbiochem, Merck KgaA, Darmstadt, 
Germany) to a final concentration of  0.5 mM. Inclusion body fractions containing rBet v 1 
trimer were isolated by an enzymatic treatment using lysozyme (0.1 mg/g cells) (Sigma-
Aldrich, St. Louis, MO, USA) and benzonase (6 U/g cells) (Merck KgaA, Darmstadt, 
Germany), followed by repetitive freezing and thawing in a buffer containing 50 mM Trisbase 
pH 8.0, 1 mM EDTA and 0.1 % v/v Triton X-100 (5 ml/ g cells). After the freezing and 
thawing, NaCl and EDTA were added to a final concentration of 200 mM and 2 mM, 
respectively, and the suspension was centrifuged (10.000 g for 30 min at 4°C) leaving Bet v 1 
trimer containing inclusion bodies in the pellet. After washing the pellet (3 times with 1% v/v 
Triton, 2 mM EDTA, 2 mM ß-mercaptoethanol, 20 mM Tris/HCl pH 8.0 and 2 times with 
50% ethanol, 20mM Tris/HCl pH 8.0), inclusion bodies were suspended and stirred for 15 
min in buffer A (6 M urea, 10 mM Tris, 1 mM EDTA, pH 8.0). After centrifugation (10.000 g 
for 30 min at 4°C), the protein was applied to a DEAE sepharose column (Amersham 
Biosciences, Uppsala, Sweden) and equilibrated with buffer A. The protein was eluted with a 
linear gradient from 0-500 mM NaCl in buffer A. Fractions containing Bet v 1 trimer as the 
major component were identified by SDS-PAGE, pooled, and dialyzed against buffer B (6M 
urea, 10 mM NaH2PO4, 1mM EDTA, pH 4.8).  
The Bet v 1 trimer was rechromatographed on an SP sepharose (Amersham Biosciences, 
Uppsala, Sweden) and equilibrated with buffer B. Protein was eluted with a linear gradient 
from 0-500 mM NaCl in buffer B. Fractions containing pure Bet v 1 trimer as the major 
component were identified by SDS-PAGE, pooled, and dialyzed stepwise against 5 mM 
sodium phosphate buffer pH 7.4 containing decreasing concentrations (6-0 M) of urea. 
Finally, the protein was subjected to 0.2 µm filtration. 
The purity of the protein preparations was checked by SDS-PAGE and Coomassie Blue 
staining and the presence of endotoxins was assessed by endotoxin testing (QCL-1000R 
Chromogenic LAL Endpoint Assay, Bio-Whittaker, Walkersville, USA). The concentration of 
rBet v 1 and rBet v 1 trimer was checked by colorimetric detection and quantification of total 
protein using bicinchoninic acid (BCA) as the detection reagent for Cu+1(Micro BCATM 
Protein Assay Kit, Thermo Scientific, Pierce, Rockford, USA). Tests were performed in 
triplicates. Diluted protein samples (0.5-20 μg /ml) were incubated for 1 hour at 60°C and the 
absorbance was measured at 562 nm according to the assay protocol. Determinations of 
protein concentrations were performed for all of the proteins in parallel in order to ensure that 
the concentrations of the different proteins can be directly compared. Determinations of the 
protein concentrations were also repeated for each of the proteins shortly before experiments 
were performed (e.g., IgE antibody reactivity testing, IgE inhibition assays, CD analysis, 
basophil activation experiments, gel filtration), in order to exclude that results are influenced 
by alterations in the protein concentrations. 
Supplementary Information 2: Immunoblottting: 
For this Western blotting, 5μg of each protein/slot was separated by SDS-PAGE (18) and 
blotted onto nitrocellulose. Nitrocelluloses containing blotted proteins were incubated either 
with a 1:2000 dilution of a rabbit anti-rBet v 1 fragment 1 or fragment 2 specific anti-serum, 
or with 1:10 dilutions of sera from eleven birch pollen allergic individuals or serum from one 
non-allergic individual. Bound IgG and IgE antibodies were detected with a 1:1000 dilution 
of 125I-labeled donkey anti-rabbit antibodies and a 1:20 dilution of 125I-labeled anti-human IgE 
antibodies (RAST RIA, Demeditec Diagnostics, Germany), respectively. Bound 125I-labeled 
antibodies were visualized by autoradiography (9). 
Supplementary Information 3: Mass spectrometry 
Matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectra were 
acquired in a linear mode on a Microflex mass spectrometer (Bruker, Billerica, MA, USA) 
equipped with a 337 nm ultraviolet laser (150 μJ at 337 nm). Hundred single laser shots were 
averaged for each mass spectrum. Samples were dissolved in 10 % acetonitrile (0.1 % 
trifluoroacetic acid), and dihydroxybenzoic acid (dissolved in 60 % acetonitrile, 0.1 % 
trifluoroacetic acid) was used as a matrix. For sample preparation a 1:1 mixture of protein and 
matrix solution was deposited onto the target and air-dried. 
 
Supplementary Information 4: IgE and IgG reactivity of rBet v 1 and rBet v 1 trimer by 
dot blot, ELISA and ELISA inhibition 
 
For dot blot experiments, two μL aliquots containing 1μg of purified rBet v 1, rBet v 1 trimer, 
bovine serum albumin (BSA) and human serum albumin (HSA) (negative controls) (Roth, 
Karlsruhe, Germany) were dotted on nitrocellulose membranes. Nitrocellulose membranes 
containing dot-blotted proteins were incubated with a 1:10 dilution, in PBS, of sera from 
eleven birch pollen allergic individuals, one non-allergic individual or buffer without addition 
of serum. Bound IgE antibodies were detected with a 1:20 dilution of 125I-labeled anti-human 
IgE antibodies (RAST RIA, Demeditec Diagnostics, Germany) and visualized by 
autoradiography (9). 
ELISA plates (Greiner, Kremsmünster, Austria) were coated with rBet v 1, rBet v 1 trimer or 
BSA (5 μg in100 μl/well diluted in PBS) at 4°C overnight. Plates were blocked with 2 % w/v 
bovine serum albumin (BSA) (Roth, Karlsruhe, Germany) in PBS-T (PBS + 0.05 % v/v 
Tween 20) for 6 hours, and incubated either with rabbit anti-Bet v 1, rabbit anti-Bet v 1 
fragment 1, rabbit anti-Bet v 1 fragment 2, rabbit anti-Bet v 1 trimer, or pre-immune sera in 
four different dilutions (1:1000, 1:5000, 1:10000 and 1:50000), in PBS 0.5 % w/v BSA/ 0.05 
% v/v Tween, at 4°C overnight. Bound rabbit IgG antibodies were detected with a 1:1000 
diluted anti-rabbit IgG, Horseradish Peroxidase-linked whole antibody from donkey (GE 
Healthcare, UK Limited) for 1 hour at 37°C and for 1 hour at 4°C. 
Detection of rBet v 1 trimer and rBet v 1 with mouse monoclonal antibodies was performed 
as follows. Plates were coated with rBet v 1, rBet v 1 trimer or BSA (5 μg in100 μl/well, 
diluted in PBS) at 4°C overnight, and then incubated either with mouse monoclonal IgG 
antibodies against peptide 2 (mAb#2) (aa 30-59) or peptide 6 (mAb#12) (aa 74-104) from Bet 
v 1, with mouse monoclonal antibody (4A6), with Bip 1 or with mouse monoclonal IgG1 
(murine anti-IgE) in four different dilutions (1:1000, 1:5000, 1:10000 and 1:50000), in PBS 
0.5 % BSA/ 0.05 % Tween, at 4°C overnight. Bound mouse monoclonal IgG antibodies were 
detected with a 1:1000 diluted anti-mouse IgG, Horseradish Peroxidase-linked whole 
antibody from sheep (GE Healthcare, UK Limited) for 1 hour at 37°C and 4°C.  
Plates were washed with PBS-T (PBS + 0.05 % Tween 20) between incubation steps and 
color development was performed by addition of  staining solution ABTS (2,2'-Azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) diammonium salt; Sigma-Aldrich, St.Louis, Missouri, 
USA) (100μl/well). The optical density was measured in an ELISA Reader (Dynatech, 
Denkendorf, Germany) at 405 nm. Results represent means of duplicate determination with a 
variation of ≤ 10 %. 
 
IgE ELISA inhibition assay 
ELISA plates (Greiner, Kremsmünster, Austria) were coated with 100μl of rBet v 1, rBet v 1 
trimer or BSA (5 μg in 100 μl/well, diluted in PBS) for six hours at room temperature. Plates 
were blocked with 2% bovine serum albumin (BSA) (Roth, Karlsruhe, Germany) in PBS-T 
(PBS 0.05% Tween 20) at 4˚C overnight. Sera from eleven birch allergic individuals (1:4 
diluted in PBS) were preincubated overnight at 4˚C with increasing concentrations (0.5 ng - 5 
μg) of the rBet v 1, rBet v 1 trimer or BSA before they were applied to the plates (100 
μl/well). Bound human IgE was detected using a 1:2500 diluted AP-conjugated (alkaline 
phosphatase) mouse monoclonal anti-human IgE antibody (BD Pharmingen, San Diego, 
California, USA). Plates were washed with PBS-T (PBS + 0.05 % Tween 20) between 
incubation steps and color development was performed by addition of  staining solution 
ABTS (2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) diammonium salt; Sigma-
Aldrich, St.Louis, Missouri, USA) (100μl/well). The optical density was measured in an 
ELISA Reader (Dynatech, Denkendorf, Germany) at 405 nm. 
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 Abstract 
Background: Approximately 100 million patients suffer from birch pollen allergy. 
Objective: Rational design of recombinant derivatives of the major birch pollen allergen, Bet 
v 1, characterized by reduced IgE reactivity, preservation of sequences relevant for the 
induction of allergen-specific blocking IgG and maintenance of T cell epitopes for 
immunotherapy of birch pollen allergy.   
Methods: Three recombinant mosaic proteins derived from Bet v 1 were generated by re-
assembly of codon-optimized genes coding for Bet v 1 fragments containing the elements for 
the induction of allergen-specific blocking IgG antibodies and the major T cell epitopes. The 
proteins were expressed in Escherichia coli as recombinant mosaic molecules and compared 
with the Bet v 1 wild-type protein by chemical and structural methods, regarding IgE- and 
IgG-binding capacity, in basophil activation assays and tested for the in vivo induction of IgG 
responses which block patients‘ IgE recognition of the Bet v 1 allergen. 
Results: Three rBet v 1 mosaic proteins with strongly reduced IgE reactivity and allergenic 
activity were expressed and purified. Immunization with the recombinant hypoallergens 
induced IgG antibodies which inhibited allergic patients IgE reactivity to Bet v 1 stronger 
than those induced with the rBet v 1 wildtype allergen.  
Conclusion: We report the generation and preclinical characterization of three hypoallergenic 
rBet v 1 derivatives with favorable properties for immunotherapy of birch pollen allergy. 
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 Introduction 
Allergy to pollen from birch and related trees (e.g., alder, hazel) is one of the most important 
allergies in Northern and Middle Europe, North America and in certain parts of Australia and 
Asia 1. The cDNA coding for the culprit allergen in birch pollen allergy, Bet v 1, has been 
cloned and recombinant Bet v 1 assembling the structural, immunological and allergenic 
properties of natural Bet v 1 has been expressed in Escherichia coli 2-6. In a recently reported 
double-blind placebo-controlled  immunotherapy trial it was shown that rBet v 1 treatment 
was as effective as treatment with birch pollen extract or purified natural Bet v 1 
demonstrating that rBet v 1 can replace a complex birch pollen extract 7. In attempts to 
eliminate the risk of IgE-mediated side effects, several hypoallergenic derivatives of Bet v 1 
have been made by recombinant technology 8. Two hypoallergenic rBet v 1 derivatives (i.e., 
two rBet v 1 fragments, rBet v 1 trimer) 9, 10 have been also used for immunotherapy of birch 
pollen allergic patients 11. The clinical outcome of the study performed with the 
hypoallergenic derivatives was less successful than the study conducted with rBet v 1 which 
may have been due to factors related to the study design and the lack of a pollen season in one 
of the study centers 12. However, patients treated with the recombinant hypoallergenic Bet v 1 
derivatives tolerated more than the five-fold maintenance dose compared to the doses given in 
the rBet v 1 study and showed a blunting of the rises of the systemic IgE responses caused by 
seasonal allergen exposure 11. Moreover, there was a clear reduction of nasal symptoms in a 
subgroup of patients when objective nasal provocation testing was performed 13. Further 
clinical studies performed with a hypoallergenic derivative made by chemical denaturation of 
rBet v 1 yielded similar immunological effects as the study performed with the recombinant 
hypoallergenic Bet v 1 derivatives and demonstrated clinically efficacy up to phase III studies 
demonstrating the therapeutic usefulness of recombinant hypoallergenic molecules 14-16.  
Here we report the rational design, structural, immunological and preclinical characterization 
of three recombinant hypoallergenic Bet v 1 derivatives omitting chemical denaturation steps. 
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These derivatives were made by re-assembly of the complete Bet v 1 sequence within single 
molecules using codon-optimízed synthetic genes in which the sequences relevant for the 
induction of blocking IgG antibodies and the dominant T cell epitopes were maintained.    
 
Material and Methods 
Patients’ sera, plasmids and recombinant allergen  
Patients suffering from birch pollen allergy were characterized by case history and positive 
skin prick testing. Serum IgE Abs specific to birch pollen extract and rBet v 1 were 
determined by immuno CAP measurements (Phadia, Uppsala, Sweden) as described 3. 
Control sera were taken from two non-allergic volunteers.  
The plasmid pET 17b (Novagen Inc., Madison, WI, USA), used for the expression of rBet v1 
and of the rBet v 1 derivatives is described 17. The recombinant Escherichia coli-expressed 
(BL 21-DE3) (Stratagene, La Jolla, CA, USA) birch pollen allergen Bet v 1 (batch # 21), was 
obtained from Biomay (Vienna, Austria). 
 
Monoclonal antibodies 
Bip 1, a monoclonal antibody with specificity for the major birch pollen allergen Bet v 1, is 
described 18. The mouse mAb 4A6 was raised against purified recombinant birch pollen 
profilin 19. Anti-IgE mAb E-124.2.8 was purchased from Immunotech (Marseille, France). 
Mouse IgG mAbs against peptide 2 (mAb#2) (aa 30-59) and against peptide 6 (mAb#12) (aa 
74-104) of Bet v 1 were obtained by immunization of mice using KLH-coupled synthetic 
peptides (peptide 2: LFPKVAPQAISSVENIEGNGGPPTIKKISF; peptide 6: 
EDVHTNFKYNYSVIEGGPIGDTLEKISNEIK).  
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Construction of hypoallergenic Bet v 1 derivatives  
Based on the Bet v 1 sequence 2, synthetic genes were generated giving rise to three different 
recombinant Bet v 1 derivatives: Restructured Bet v 1 #1 (Bet v 1-rs1) comprising amino 
acids 75-160 + 1-74,  Restructured Bet v 1 #2 (Bet v 1 rs2) comprising amino acids 110-160 + 
1-109, and Bet v 1 mosaic comprising amino acids 110-160 + 60-109 + 1-59 (Fig. 1A). 
The synthetic genes of each of the recombinant Bet v 1 derivatives were cloned into the 
pET17b (Novagen Inc., Madison, WI, USA) cloning vector via NdeI and EcoRl restriction 
sites. The coding sequences were optimized for expression in E.coli and the correct sequence 
of the derivative molecules was confirmed by double stranded DNA sequencing (Eurofins 
Medigenomix GmbH, Ebersberg, ATG Biosynthetics GmbH, Merzhausen, Germany). 
 
Expression and purification of the recombinant hypoallergenic Bet v 1 derivatives 
The plasmids containing the reassembled constructs were transformed into the E.coli BL 21 
(DE3) expression strain (Stratagene, LA Jolla, CA, USA). Batch fermentation of E.coli BL 21 
(DE3) transformed with pET-17b-Bet v 1-rs1, -rs2 or mosaic was carried out at 37°C in a 10 
L fermenter (New Brunswick, Bioflow 3000) in LB medium with the addition of 0.05 % (v/v) 
glycerol, 0.25 % (w/v) MgSO4 . 7 H2O, and 0.18 % Na2HPO4 . 2 H2O for 8 h at 37°C until a 
cell density (OD600nm) of  0.4 to 0.6 was reached. Protein expression was induced by adding 
0.5 mM isopropyl-β-thiogalactopyranoside (IPTG) (Calbiochem, Merck, Darmstadt, 
Germany). Recombinant proteins were produced as described in supplementary information 
#1. 
 
Detection of IgG binding capacity of rBet v 1 and rBet v 1 derivatives 
Purified recombinant Bet v 1 and rBet v 1 derivative molecules were tested for reacting with 
specific antibodies. Five μg of each protein/slot was separated by SDS-PAGE 20 and blotted 
onto nitrocellulose 21. Nitrocellulose blotted proteins were incubated either with a 1:2000 
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dilution of a rabbit anti-rBet v 1 or the corresponding  pre-immune serum, or with a 1:1000 
dilution of  mouse monoclonal IgG antibodies. Bound IgG antibodies were detected with a 
1:1000 dilution of 125I-labeled goat anti-rabbit antibodies or with a 1:1000 dilution of 125I-
labeled goat anti-mouse antibodies (NEN Life Science Products, Inc., Boston, Massachusetts, 
USA) and visualized by autoradiography 9. 
 
IgE reactivity of dot-blotted rBet v 1 and Bet v 1 derivatives 
IgE reactivity of purified rBet v 1 derivatives was tested and compared to rBet v 1 by dot blot 
assays. Two μL aliquots containing 1μg of purified rBet v 1, each of the rBet v 1 derivatives, 
bovine serum albumin (BSA) and human serum albumin (HSA) (negative control proteins) 
(Roth, Karlsruhe, Germany) were dotted onto nitrocellulose. Nitrocellulose were incubated 
with sera from nineteen birch pollen allergic individuals, two non-allergic individuals or 
buffer without addition of serum. Bound IgE antibodies were detected with a 1:20 dilution of 
125I-labeled anti-human IgE antibodies (RAST RIA, Demeditec Diagnostics, Germany). The 
presence of rBet v 1 and rBet v 1 derivatives on the nitrocellulose membrane was shown with 
rabbit anti-rBet v 1 antibodies, which were detected with 1:1000 dilution of 125I-labeled 
donkey anti-rabbit antibodies (RAST RIA, Demeditec Diagnostics, Germany). 
 
Immunization of rabbits and determination of IgG antibody levels 
Rabbits were immunized twice, at study day 0 and at study day 28, with 200 μg of purified 
rBet v 1, rBet v 1-rs1, rBet v 1-rs2, or rBet v 1-mosaic initially adsorbed to CFA (Complete 
Freund’s adjuvant) and followed by booster injection using IFA (Incomplete Freund’s 
adjuvant). Pre-immune sera were obtained from the rabbits before immunization (Charles 
River Breeding Laboratories, Kisslegg, Germany). 
ELISA plates (Greiner, Kremsmünster, Austria) were coated with rBet v 1, rBet v 1-rs1, rBet 
v 1-rs2, rBet v 1-mosaic or BSA (negative control) (5 μg/ml diluted in PBS) at 4°C overnight. 
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After washing three times with PBS-T (PBS + 0.05 % Tween 20) and blocking with 2 % 
bovine serum albumin (BSA) (Roth, Karlsruhe, Germany) in PBS-T for 6 hours, plates were 
incubated either with rabbit anti-Bet v 1, rabbit anti-Bet v 1-rs1, rabbit anti-Bet v 1-rs2, or 
with rabbit anti-Bet v 1-mosaic in five different dilutions (1:1000, 1:5000, 1:10000, 1:100000 
and 1:1000000), made in 0.5 w/vol % BSA in PBS-T, at 4°C overnight. Controls were 
performed with normal rabbit antibodies. Plates were washed five times with PBS-T and 
bound rabbit IgG antibodies were detected with a 1:1000 diluted anti-rabbit IgG Horseradish 
Peroxidase linked whole antibody from donkey (GE Healthcare, UK Limited) for 1 hour at 
37°C and 4°C. After washing with PBS-T (5 times) the color development was performed by 
addition of staining solution ABTS (2,2'-Azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
diammonium salt; Sigma-Aldrich, St.Louis, Missouri, USA) (100μl/well). The optical density 
was measured using an ELISA Reader (Dynatech, Denkendorf, Germany) at 405 nm.  
 
Allergenic activity of allergen derivatives 
The allergenic activity of allergen derivatives was compared with that of the Bet v 1 wildtype 
allergen using CD203c assays as described in supplementary information #2.  
 
Inhibition of allergic patients’ IgE binding to Bet v 1 by IgG antibodies 
The inhibition of allergic patients’ IgE binding to Bet v 1 by IgG antibodies was shown as 
described in supplementary information #3.  
 
Results 
Rationale construction of hypoallergenic rBet v 1 derivatives  
It has been shown that two recombinant fragments of Bet v 1 comprising amino acids 1-74 
and 75-160 preserved the Bet v 1-specific T cell epitopes but exhibited an approximately 100 
fold reduced allergenic activity compared to rBet v 1 as shown in vitro by basophil activation 
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testing and in several in vivo provocation studies 9, 22-25. Each of these fragments contains a 
peptide defined by two monoclonal antibodies mAb#2 (aa 30-59) and mAb#12 (aa 74-104) 
which induced Bet v 1-specific IgG antibodies inhibiting the binding of birch pollen allergic 
patients IgE to Bet v 1 26 (Fig. 1A). The first Bet v 1 derivative, designated Bet v 1-rs1, was 
made by re-assembling the hypoallergenic fragments aa 1-74 and aa 75-160 within one 
molecule as a tail-to-head construct as described for a Phl p 12 derivative 27 (Fig. 1A). The 
second Bet v 1 derivative, designated Bet v 1-rs2, was prepared by re-assembling aa 1-109 
which contains three peptides (P2: aa 30-59; P3: aa 50-79;  and P6: aa 74-104) that had 
induced strong blocking IgG antibody responses against Bet v 1 26 at the C-terminus and a 
portion comprising aa 110-160 at the N-terminus. Because of the possibility that the fragment 
aa 1-109 might regain allergenic activity, it was broken into two pieces, aa 60-109 containing 
P6 and aa 1-59 containing P2, and a mosaic was constructed from these pieces. This mosaic, 
designated Bet v 1-mosaic, consists of Bet v 1 portions aa 110-160, aa 60-109 and aa 1-59 
from the N- to the C-terminus (Fig. 1A).  
 
High level expression, purification, structural and immunochemical characterization of 
rBet v 1 derivatives 
Using the plasmids containing the cDNAs coding for the three Bet v 1 derivative molecules 
(Bet v 1-rs1, Bet v 1-rs2 and Bet v 1-mosaic) high level expression of the recombinant 
proteins yielding more than 20% of the total E. coli proteins was obtained. Each of the 
recombinant proteins could be purified from the inclusion body fraction of the bacteria via 
several chromatography steps to more than 90 % purity (Fig. 1B). There was no sign of 
aggregation of the proteins which yielded single bands both under reducing as well as non-
reducing conditions in SDS-PAGE (data not shown). The experimentally determined mass 
was in good agreement with the mass calculated from the deduced amino acid sequence (data 
not shown). The overall secondary structure contents of the three recombinant Bet v 1 
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derivatives were compared with that of rBet v 1 by CD. In contrast to rBet v 1, which 
exhibited the typical fold of a mixed α helical and ß sheet containing protein, all three rBet v 1 
derivatives were unfolded (data not shown).  
Next we used Bet v 1-specific antibody probes to test IgG reactivity of the Bet v 1 derivatives. 
Nitrocellulose-blotted rBet v 1 and rBet v 1 derivatives reacted with the polyclonal rabbit 
antibodies which had been raised against rBet v 1 (Fig. 2A). Interestingly, the monoclonal 
antibody Bip 1 which recognizes conformational epitopes of Bet v 1 reacted only with the 
folded rBet v 1 wild type protein but not with the unfolded rBet v 1 derivatives (Fig. 2B). The 
mAbs specific for P2 (mAb#2) (aa 30-59) and for P6 (mAb#12) (aa 74-104) reacted with rBet 
v 1 and each of the three rBet v 1 derivatives (Figs. 2C-D). The rabbits pre-immune serum 
and an isotype-matched mouse monoclonal antibody without specificity for Bet v 1 did not 
show any binding (data not shown).  
 
Comparison of the IgE reactivity of rBet v 1 and rBet v 1 derivatives   
Aliquots of rBet v 1, rBet v 1-rs1, rBet v 1-rs2 or rBet v 1-mosaic were dotted under non-
denaturing conditions onto nitrocellulose membranes. We found that none of the 19 birch 
pollen allergic patients tested exhibited any detectable IgE reactivity to the rBet v 1 
derivatives whereas they showed IgE-binding to rBet v 1 (Fig. 3, lanes 1-19). No IgE 
reactivity to the control proteins HSA and BSA was found. Serum IgE from non-allergic 
individuals and buffer showed no reactivity to any of the proteins (Fig. 3, lanes 20-21, 0). 
The presence of rBet v 1 and rBet v 1 derivatives on the membrane was confirmed by testing 
with rabbit anti-rBet v 1 antibodies (Fig. 3, lane 22).  
 
Reduced allergenic activity of rBet v 1 derivatives 
In a first set of experiments, we compared rBet v 1-rs1 with rBet v 1 and an equimolar mix of 
rBet v 1 fragments for their allergenic activity using basophils from birch pollen allergic 
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patients. rBet v 1-rs1 did not cause any upregulation of the CD203c expression up to the top 
concentration (i.e., 50 pM) tested in the six patients whereas rBet v 1 started to induce 
basophil activation already at 0.5 pM and each of the patients responded to 50 pM. rBet v 1-
rs1 exhibited even lower allergenic activity than the rBet v 1 fragment mix which induced 
CD203c upregulation at 5pM in one patient and at 50 pM in two of the 6 patients (Fig. 4A). 
We then compared the three rBet v 1 derivatives with rBet v 1 regarding allergenic activity 
using basophils from additional 4 patients (Fig. 4B). In three patients, rBet v 1 derivatives did 
not induce any CD203c upregulation up to the top concentration of 50 pM, whereas rBet v 1 
caused activation at 5 pM. In the fourth patient, the rBet v 1 derivatives showed a 100-fold 
reduction of allergenic activity compared to rBet v 1 (Fig. 4B).   
 
Immunization with rBet v 1 derivatives induces IgG antibodies which recognize Bet v 1 
and strongly inhibit patients IgE binding to Bet v 1  
As shown in Figure 5, rabbits immunized with the rBet v 1 derivatives showed an almost 
comparable IgG response to rBet v 1 wild type as the rabbit immunized with rBet v 1 (Fig. 
5A). Rabbit anti-rBet v 1 antibodies reacted with the rBet v 1 derivatives albeit somewhat 
weaker than the anti-rBet v 1 derivative antibodies (Figs. 5B-D).   
We then investigated whether rBet v 1 derivative-induced rabbit IgG antibodies can inhibit 
the binding of patients’ serum IgE to the wild-type rBet v 1 in an ELISA competition assay. 
The anti-rBet v 1-rs1 antiserum inhibited the binding of birch pollen allergic patients’ IgE to 
rBet v 1 between 56.5 % and 98 % (85 % mean inhibition). The anti-rBet v 1-rs2 antiserum 
showed inhibition rates between 59.5 % and 98.5 % (87 % mean inhibition) and the anti-rBet 
v 1-mosaic inhibited between 58 % and 99.5 % (82 % mean inhibition). Interestingly, the 
rabbit antiserum against rBet v 1 derivatives showed higher average inhibition rates than the 
anti-rBet v 1 antibodies which yielded only 62 % mean inhibition of IgE binding to rBet v 1 
(Table 1). 
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Discussion 
In this study we constructed by rational molecular reassembly three recombinant 
hypoallergenic derivatives of the major birch pollen allergen, Bet v 1 for immunotherapy. The 
recombinant Bet v 1 fragments which have been re-assembled as a tail-to-head construct for 
the first derivative, Bet v 1-rs1, have been evaluated regarding their allergenic activity in 
several skin test and provocation test studies in birch pollen allergic patients showing a 
consistent reduction of allergenic activity 5, 9, 23, 11, 7, 24. This first hypoallergenic derivative 
also exhibited a strongly reduced allergenic activity. Similar results were obtained for the 
second re-assembled molecule although we maintained in Bet v 1-rs2 the portions necessary 
for the induction of IgG antibodies against the IgE binding sites of Bet v 1 in a large fragment 
comprising aa 1-109 which was preceded by a smaller portion comprising aa 110-160 
containing the major T cell epitope of Bet v 1 28. The third derivative, designated Bet v 1-
mosaic was made similar as Bet v 1-rs2. Again the C-terminal portion aa 110-160 carrying the 
major T cell epitope was placed at the N-terminus but the portion aa 1-109 responsible for the 
induction of blocking antibodies was disrupted again to eliminate possible IgE reactivity to 
such a large fragment. The fragment aa 1-109 was therefore re-assembled by two fragments 
containing two peptides which have been shown to induce blocking IgG responses 26.  
All three rBet v 1 derivatives could be expressed at high levels in an E. coli expression system 
and purified via several chromatography steps close to homogeneity. They showed no signs of 
aggregation, and were recognized by antibodies raised against those peptides which induced 
blocking antibody responses against Bet v 1. A monoclonal antibody, Bip 1, which recognizes 
a conformational epitope on Bet v 1 did not react with the three derivatives indicating that 
their three-dimensional structure is altered compared to Bet v 1. The latter assumption was 
confirmed by CD measurements demonstrating that the three derivatives represented unfolded 
molecules. 
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The three derivatives lacked relevant IgE reactivity as already observed for the unfolded rBet 
v 1-fragments and exhibited an even greater reduction of allergenic activity than a mix of the 
two fragments 9. The three recombinant Bet v 1 derivatives therefore show important 
advantages over the previously characterized rBet v 1 fragments. They combine both 
molecules within one protein which can be easily expressed in large amounts in E. coli. 
Furthermore, their allergenic activity seems to be even lower than that of the fragments.  
Several in vitro results as well as immunotherapy studies indicate that blocking IgG 
antibodies are involved in protection against allergic immune responses. It has been shown 
that allergen-specific blocking IgG inhibits immediate and late-phase responses. Moreover, 
allergen-specific blocking IgG antibodies inhibit the boosts of IgE production induced by 
allergen contact 11, 31.  
In fact, a recent immunotherapy study performed with rBet v 1 demonstrated that the 
reduction of clinical symptoms and skin sensitivity was associated with the production of 
allergen-specific IgG responses 7. 
Therefore immunization experiments with the three rBet v 1 derivatives were performed and 
it was shown that the derivatives induced comparable IgG responses to the Bet v 1 wild-type 
allergen as Bet v 1 wildtype itself.  
Even more important we found that the IgG antibodies induced with each of the three rBet v 1 
derivatives inhibited the binding of birch pollen allergic patients’ IgE to the Bet v 1 allergen 
better than those induced with the folded rBet v 1 wildtype molecule. This result was quite 
unexpected but may be attributed to the fact that we have maintained those peptides in the 
rBet v 1 derivatives, which were involved in the induction of blocking antibodies.  
We believe that the strategy of allergen fragmentation and consecutive systematic 
recombination in the form of mosaic molecules has advantages over the use of small 
hypoallergenic allergen fragments because small protein fragments may exhibit lower 
immunogenicity and induce low allergen-specific IgG antibodies. In addition, the generation 
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of one single reassembled molecule may facilitate the production and purification steps 8. We 
did not have the chance to compare the three rBet v 1 hypoallergens with the recently 
described rBet v 1 derivative obtained by the shuffling of DNA sequences from Bet v 1, Aln g 
1 and Cor a 1 but it is likely that their allergenic activity is lower because the IgE reactivity of 
the shuffled constructs was reduced only 8-20 fold 29 whereas we could not detect any IgE 
binding to the three derivatives at least in those patients which we tested.  
The three recombinant derivatives characterized here may also have several advantages over a 
hypoallergenic rBet v 1 folding variant which has been successfully used for immunotherapy 
of patients 14, 16. The folding variant exhibited residual IgE reactivity and needs to be 
produced by chemical modification 14 of the rBet v 1 molecules whereas the hypoallergenic 
derivatives described here can be obtained directly by recombinant expression. The mosaic 
approach used by us also seems to have the advantage to be generally applicable to allergenic 
molecules from different sources 30, 31. 
In conclusion, the hypoallergenic Bet v 1 derivatives described here may be considered 
promising candidate molecules for active vaccination but also for the induction of tolerance 32, 
33. Moreover, their genes may be useful for gene therapy and genetic immunization protocols 
34, 35 because the resulting proteins exhibit reduced allergenic activity. 
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Figures and Table 
Figure 1.  Hypoallergenic rBet v 1 derivatives. (A) Construction scheme of the rBet v 1 
derivatives (Bet v 1-rs1, Bet v 1-rs2, Bet v 1-mosaic). The amino acids at the borders of the 
protein segments and the binding sites of two monoclonal antibodies mAb#2 and mAb#12 are 
indicated. (B) SDS-PAGE of purified rBet v 1 and rBet v 1 derivatives. Comparison of 
purified recombinant Bet v 1 and rBet v 1 derivatives. M, molecular mass markers (kDa). 
 
Figure 2. IgG reactivity of rBet v 1 and rBet v 1 derivatives with Bet v 1-specific antibodies. 
Nitrocellulose blotted rBet v 1 and rBet v 1 derivatives were probed with rabbit anti-Bet v 1 
antibodies (rαBet v 1) (A), mAb Bip 1 (B), mAb#2 (C) or mAb#12 (D). Molecular weights 
are displayed on the right margins in kilo Daltons (kDa). 
 
Figure 3. IgE-reactivity of rBet v 1 and rBet v 1derivatives. Nitrocellulose-dotted rBet v 1, 
rBet v 1- rs1, rBet v 1- rs2 and rBet v 1-mosaic as well as HSA and BSA were exposed to sera 
from 19 birch pollen allergic patients (lanes 1-19), two non-allergic individuals (lanes 20-21) 
buffer (0) or rabbit anti-rBet v 1 antibodies (lane 22). Bound IgE and rabbit IgG antibodies 
were detected and visualized by autoradiography. 
 
Figure 4. Allergenic activity of rBet v 1 and rBet v 1 derivatives as determined by CD203c 
upregulation on allergic patients basophils. (A) Blood samples from six birch-allergic patients 
(A-F) were exposed to increasing concentrations (0.005 to 50 pM) of rBet v 1, an equimolar 
mixture of rBet v 1 fragments (F1+F2) or rBet v 1- rs1 (x-axes). (B) Incubation of blood 
samples from additional four birch pollen allergic individuals (G-J) with increasing 
concentrations (0.005 to 50 pM) of rBet v 1, rBet v 1-rs1, rBet v 1-rs2, rBet v 1-mosaic (x-
axes). Anti-IgE served as a positive control. The stimulation indices (SI) (y-axis) reflect the 
up-regulation of CD203c expression compared to buffer (0). 
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Figure 5. Reactivity of rabbit anti-rBet v 1 or anti-rBet v 1 derivative antibodies with rBet v 1 
and rBet v 1 derivatives. Different dilutions (x-axes) of rabbit anti-rBet v 1 (anti-Bet v 1: ●), 
anti-rBet v 1derivative antibodies (anti-Bet v 1- rs1: ■; anti-Bet v 1-rs 2: ▲; anti-Bet v 1- 
mosaic: x) or antibodies from a normal rabbit (▬) were reacted with rBet v 1 (A), rBet v 1-
rs1 (B), rBet v 1-rs2 (C) or rBet v 1-mosaic (D). Optical density (OD) values (y-axes) 
correspond to the amounts of bound antibodies. 
 
Table 1. Inhibition of allergic patients’ IgE-binding to rBet v 1 by IgG antibodies. rBet v 1 
was pre-incubated with rabbit IgG antibodies raised against rBet v 1, rBet v 1-rs1, rBet v 1- 
rs2, rBet v 1-mosaic or the corresponding rabbit pre-immune sera (nrs) and then exposed to 
sera from 18 birch pollen allergic patients. The OD values correspond to the amounts of 
bound IgE antibodies. Percentages (%) inhibition of patients’ IgE-binding to rBet v 1 obtained 
with each antiserum versus the pre-immune sera as well as the mean inhibition values are 
displayed.  
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Table 1. Inhibition of allergic patients’ IgE-binding to rBet v 1 by IgG antibodies
% inhibition % inhibition % inhibition % inhibition
Patient nrs rα Bet v 1 rα Bet v 1 nrs α Bet v 1rs 1 α Bet v 1rs1 nrs α Bet v 1rs 2 α Bet v 1rs2 nrs α Bet v 1mosaic α Bet v 1mosaic
1 0.111 0.066 40.5 0.121 0.037 69.5 0.13 0.036 72 0.131 0.044 66.5
2 0.353 0.15 57.5 0.404 0.082 79.7 0.433 0.071 83.5 0.477 0.117 75.5
3 1.055 0.269 74.5 1.193 0.06 95 1.248 0.049 96 1.445 0.085 94
4 0.306 0.093 69.6 0.336 0.038 89 0.357 0.035 90 0.391 0.047 88
5 0.508 0.14 72.5 0.612 0.052 91.5 0.657 0.049 92.5 0.674 0.061 91
6 3.211 0.466 85.5 3.335 0.095 98 3.471 0.047 98.5 3.601 0.408 89
7 1.662 0.483 71 1.902 0.074 96 2.026 0.063 97 2.098 0.154 93
8 0.125 0.086 31 0.14 0.033 76.5 0.142 0.033 77 0.149 0.045 70
9 0.991 0.374 62 0.442 0.128 71 0.452 0.092 79.6 0.466 0.171 64
10 1.571 0.315 80 1.546 0.063 96 1.817 0.04 98 1.977 0.219 89
11 0.582 0.245 58 0.655 0.039 94 0.689 0.027 96 0.704 0.074 89.5
12 1.32 0.154 88.5 1.641 0.063 96 1.833 0.048 97 2.051 0.109 95
13 1.424 0.361 74.7 1.573 0.048 97 1.682 0.038 98 1.705 0.12 99.5
14 0.158 0.127 19.6 0.16 0.06 62.5 0.177 0.061 65.5 0.198 0.068 66
15 0.098 0.057 41.8 0.106 0.046 56.5 0.111 0.045 59.5 0.111 0.047 58
16 0.617 0.073 88 0.738 0.049 93 0.805 0.047 94 0.805 0.086 89
17 0.523 0.134 74.4 0.546 0.048 91 0.586 0.041 93 0.602 0.071 88
18 0.118 0.083 29.7 0.126 0.035 72 0.135 0.033 75.5 0.144 0.04 72
62 85 87 82% mean inhibition
OD values OD values OD values OD values
Supplementary Table I. Demographic, serologic, and clinical characterization of the individuals
- (A-H) represent the subjects studied by CD203c expression experiments 
- M, Male; F, Female; RC, rhinoconjunctivitis; AD, atopic dermatitis; AS, asthma; OAS, oral allergy syndrome
- AH, antihistaminicos; BD, bronchodilator; TCt, topical corticosteroids, SIT, specific-immunotherapy; UV, ultraviolet-light therapy; no, no therapy at the time of analysis
- a, animals; g, grass; pf, plant food; npf, non-plant-derived food; mo, molds; mi, mites; w, weeds; 0, no allergy
Allergic Total IgE 
Subjects Sex/Age Birch rBet v 1 (kU/L) Other allergies
1 M/56 15.7 14.6 860 a, g, pf, npf, mo, mi
2 M/44 27.4 27.1 69.3 pf
3 (C) M/28 76.4 16.84 >5000 a, g, pf, npf, mo, mi, w
4 (H) M/27 15.4 10.1 281 a, pf, mi
5 M/47 25.6 20.2 114 a, g, pf, mi
6 M/38 >200 >200 >10000 a, g, pf, npf, mo, mi, w
7 F/46 >100 26 >5000 a, g, pf, npf, mo, mi, w
8 M 12 13.66 3674 a, g, pf, npf, mi, w
9 F/42 145.4 47.8 >10000 a, g, pf, npf, mi, w
10 (F) M/29 98.1 >100 760 a, g, pf, npf, mo, mi, w
11 F 170.6 85.2 6192 a, g, pf, npf, mo, mi, w
12 F/46 57.5 60.5 466 a, g, pf, mi
13 (A) F/30 >100 >100 >5000 a, g, pf, npf, mo, mi, w
14 (B) M/29 12.4 10.4 285 pf
15 (E) M/42 1.01 1 36.1 mi
16 (D) F/30 4.87 3.41 144 a, g, pf, npf, mi
17 M/47 37.1 28.7 144 a, g, pf, mo, w
18 M/52 36.9 36 115 pf
19 M/51 8.45 7.41 29.7 g, pf, mi
(G) M/32 6.61 3.88 102 a, g, pf, npf, mi,mo, w
(I) M/23 24.8 21.7 233 a, g, pf, npf, mo, mi, w
(J) F/30 58.7 47 4886 a, pf, mo, w
Non-Allergic
Subjects
20 F/28 <0.35 <0.35 <2.00 0
21 F/34 <0.35 <0.35 2.65 0
RC AH, SIT
-
-
no
no
RC AH
RC, AD,AS, OAS AH, BD
RC AH, BD, TCt
RC AH, TCt
RC no
RC, OAS no
RC no
RC no
RC, AS, OAS no
RC, OAS AH
RC AH
RC, AD no
RC, AD AH, TCt, UV
RC, AD, AS AH, SIT
RC, AD AH, TCt
RC, AD TCt
RC, AD AH, TCt
RC, AD, OAS no
RC, AD AH
RC, AD AH, TCt, SIT
 related symptoms  treatment
RC, AD, AS, OAS AH, TCt
Birch pollen Type of IgE CAP (kUA/L)
Supplementary Information # 1: Purification and characterization of recombinant 
hypoallergens 
 
Inclusion bodies were isolated from the cells using lysozyme (0.1 mg/ g cell wet weight) 
(Sigma-Aldrich, St. Louis, MO, USA) and repetitive freezing and thawing in buffer I (50 mM 
Tris base, 1 mM EDTA and 0.1 % Triton X-100) for Bet v 1-rs1 and Bet v 1-mosaic, or buffer 
II (25 mM NaH2PO4, pH 7.4 and 0.1 % Triton X-100) for Bet v 1-rs 2 (5 mL/ g cell wet 
weight). NaCl was added to a final concentration of  200 mM, and the suspensions were 
centrifuged (10000 g for 30 min. at 4°C) leaving the proteins containing inclusion bodies in 
the pellet.  
Bet v 1-rs1 and Bet v 1-rs2 pellets were washed with 1% Triton X-100, 2 mM EDTA, 2 mM 
ß-mercaptoethanol, 20 mM Tris/HCl pH 8.0 (3 times) and afterwards with 50% ethanol, 20 
mM Tris/HCl pH 8.0 (2 times). The Bet v 1-mosaic pellet was washed once with 1% Triton 
X-100, 20 mM NaH2PO4 pH 7.4 and once with 25% ethanol, 20 mM NaH2PO4 pH 7.0. 
Inclusion bodies were suspended and stirred for 30 min in buffer A (6 M urea, 10 mM 
Tris/HCl, 1 mM EDTA, pH 7.0) in case of Bet v 1-rs1, or in buffer B (5 M urea in 20 mM 
sodium acetate buffer, pH 5.0) in case of Bet v 1-rs2 and mosaic. The suspensions were 
centrifuged (10000 g for 30 min. at 4°C) and the final supernatant used for purification. 
Recombinant Bet v 1-rs1 was first purified by anion exchange chromatography (AIEC) on a 
Q-Sepharose FF column (GE Healthcare, UK Limited) by applying a linear gradient from 0-
250 mM NaCl in buffer A. Fractions containing Bet v 1-rs1 were dialyzed against buffer C (6 
M urea, 20mM NaH2PO4, 1.5 M NaCl, pH 4.5) and subjected to hydrophobic interaction 
chromatography (HIC) using a Phenyl Sepharose FF column (GE Healthcare, UK Limited) 
equilibrated with buffer C. Purified Bet v 1-rs1 was eluted with a linear gradient from 0 % to 
100 % buffer D (6 M urea, 20mM Tris base, pH 9.3) and pure fractions were dialyzed first 
against 6M urea and then against 1mM acetic acid. Finally, the protein was subjected to 0.2 
µm filtration and stored at -20°C. 
Recombinant Bet v 1-rs2 and -mosaic were purified by cation exchange chromatography 
(CIEC) using a SP-Sepharose FF column (GE Healthcare, UK Limited) equilibrated with 
buffer B and eluted with a linear gradient from 0-400 mM NaCl in the same buffer. To the 
fractions containing Bet v 1- rs2 NaCl was added to a final concentration of 1.7 M. Protein 
was centrifuged (10000 g for 30 min at 4°C) and the supernatant subjected to hydrophobic 
interaction chromatography (HIC) using a Phenyl Sepharose FF column (GE Healthcare, UK 
Limited), equilibrated with buffer E (6 M urea, 1.7 M NaCl in a 20 mM sodium acetate 
buffer, pH 5.0). Bet v 1-rs2 was then eluted with a linear gradient from 1.7 - 0 M NaCl in 
buffer E and fractions containing > 90 % pure rBet v 1-rs2  were dialyzed against buffer F (6 
M Urea, 20 mM NaH2PO4 pH 7.0) and subjected to anion exchange chromatography (AIEC) 
using a Q-Sepharose FF column (GE Healthcare, UK Limited) equilibrated with the buffer F.  
To the fractions containing Bet v 1- mosaic urea  and NaCl were added to a final 
concentration of 6.5 M and 3.5 M respectively. The protein was centrifuged (10000 g for 30 
min at 4°C) and the supernatant subjected to hydrophobic interaction chromatography (HIC) 
using a Phenyl Sepharose FF column (GE Healthcare, UK Limited), equilibrated buffer G 
(6.5 M urea, 3.5 M NaCl in a 20 mM sodium acetate buffer, pH 5.0). Bet v 1- mosaic was 
eluted with a linear gradient from 3.5 - 0 M NaCl in buffer G. 
Finally, Bet v 1-rs2 or -mosaic fractions containing > 90 % purity were pooled, dialyzed 
against 5 mM NaH2PO4 pH 7.4 and subjected to 0.2 µm filtration and stored at -20°C. 
 
Purified rBet v 1 and each of the rBet v 1 derivatives (5 μg protein/slot) were resolved on 12.5 
% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) in the presence or 
absence of 2-mercaptoethanol 1. Proteins were visualized by staining with Coomassie brilliant 
blue. The presence of endotoxin was determined in a limulus amebocyte lysate (LAL) 
chromogenic assay (QCL-1000R Chromogenic LAL Endpoint Assay, Bio-Whittaker, 
Walkersville, USA). 
 
Laser  desorption mass spectra of the proteins were acquired in a linear mode with a MALDI-
ToF instrument (Microflex, Bruker, Billerica, MA, USA). Samples were dissolved in 10 % 
acetonitrile (0.1 % trifluoroacetic acid), and sinapinic acid (dissolved in 60 % acetonitrile, 0.1 
% trifluoroacetic acid) was used as a matrix. For sample preparation a 1:1 mixture of protein 
and matrix solution was deposited onto the target and air-dried. 
CD spectra were acquired on a JASCO (Tokyo, Japan) J-810 spectropolarimeter. CD 
measurements were performed with purified rBet v 1 and rBet v 1 derivatives at room 
temperature, at protein concentrations of 0.1 mg/ml using a rectangular quartz cuvette with 
0.1-cm path length. Far ultraviolet (UV) spectra were recorded in the wavelength ranges 
between 190 and 260 nm with a resolution of 0.5 nm at a scan speed of 50 nm/min and 
resulted from averaging of three measurements. The final spectra were baseline-corrected and 
results were expressed as the mean residue ellipticity (Θ) at a given wavelength. The 
secondary structure content of  rBet v 1 and Bet v 1 derivative molecules was calculated using 
the secondary structure estimation program CDSSTR 2. 
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Supplementary Information # 2: The allergenic activity of allergen derivatives 
 
 
Heparinized peripheral blood samples were obtained from birch pollen allergic individuals 
after informed consent was given. Blood aliquots (100 µl) from six patients were incubated 
(unique) with serial dilutions (0.005 to 50 pM) of rBet v1, an equimolar mix of the rBet v 1 
fragments (F1+F2), or rBet v 1-rs 1 for 15 minutes at 37°C. Blood aliquots (100 µl) from 
additional four patients were incubated (unique) with serial dilutions (0.005 to 50 pM) of rBet 
v1, rBet v 1-rs1, rBet v 1-rs2, or rBet v 1-mosaic as described above. A monoclonal anti-IgE 
antibody E-124.2.8 (1µg/ml) (Immunotech, Marseille, France) and PBS (control buffer) were 
used as controls. Thereafter, samples were washed in PBS containing 20 mM EDTA (Gibco, 
Carlsbad, California, USA) and cells were incubated with 10 µl of PE-conjugated CD203c 
mAb 97A6 (Immunotech, Marseille, France) for 15 minutes at room temperature. After 
erythrocyte lysis using FACSTM Lysing Solution (Becton Dickinson Biosciences, San Jose, 
California, USA), cells were washed and resuspended in PBS and then analyzed by two-color 
flow cytometry on a FACSScan (Becton Dickinson Biosciences, San Jose, California, USA) 
using Flowjo Software (Tree Star Inc., Ashland, Oregon, USA). Anti-IgE-induced up-
regulation of CD203c was calculated from mean fluorescence intensities (MFIs) obtained 
with stimulated (MFIstim) and unstimulated (MFIcontrol) cells, and is expressed as stimulation 
index (MFIstim : MFIcontrol) 1.  
 
Reference:  
1. Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, et 
al. Recombinant allergens promote expression of CD203c on basophils in sensitized 
individuals. J Allergy Clin Immunol 2002; 110:102-09. 
Supplementary Information # 3: ELISA competition assay 
 
 
In order to analyze the ability of rBet v 1 derivatives-induced rabbit IgG to inhibit the binding 
of  birch pollen allergic patients’ IgE to rBet v 1, an ELISA competition assay was performed. 
ELISA plates (Greiner, Kremsmünster, Austria) were coated with 100μl of rBet v 1 (5 μg/ml 
diluted in PBS) overnight at 4˚C. Plates were blocked with 2% bovine serum albumin (BSA) 
(Roth, Karlsruhe, Germany) in PBS-T (PBS 0.05% Tween 20) for 6 hours at 4˚C overnight 
and then preincubated overnight at 4˚C with 1:50 dilutions (in PBS 0.5 % BSA/ 0.05 % 
Tween) of the rabbit sera anti-Bet v 1, anti-Bet v 1-rs1, anti-Bet v 1-rs2 or anti-Bet v 1-
mosaic, and for control purposes by using the corresponding rabbit pre-immune sera. Plates 
were washed three times with PBS-T and incubated with 1:10 diluted sera from 18 birch 
pollen allergic patients sensitized to Bet v 1. Bound human IgE antibodies were detected 
using a 1:2500 diluted AP-conjugated (alkaline phosphatase) mouse monoclonal anti-human 
IgE antibody (BD Pharmingen, San Diego, California, USA). Color development was 
performed by addition of  staining solution ABTS (2,2'-Azino-bis (3-ethylbenzthiazoline-6-
sulfonic acid) diammonium salt; Sigma-Aldrich, St.Louis, Missouri, USA) (100μl/well) and 
the optical density was measured in an ELISA Reader (Dynatech, Denkendorf, Germany) at 
405 nm. The percentage of inhibition of IgE-binding was calculated using the OD values 
obtained, as follows: percent inhibition of IgE binding = 100 – (ODs/ODp) x 100. ODs, 
extinction coefficient after preincubation with the rabbit serum. ODp,  extinction coefficient 
after preincubation with the pre-immune serum. 
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A Combination Vaccine for Allergy and Rhinovirus Infections
Based on Rhinovirus-Derived Surface Protein VP1 and a
Nonallergenic Peptide of the Major Timothy Grass Pollen
Allergen Phl p 11
Johanna Edlmayr,* Katarzyna Niespodziana,* Birgit Linhart,* Margarete Focke-Tejkl,*
Kerstin Westritschnig,* Sandra Scheiblhofer,§ Angelika Stoecklinger,§ Michael Kneidinger,†
Peter Valent,† Raffaela Campana,* Josef Thalhamer,§ Theresia Popow-Kraupp,‡
and Rudolf Valenta2*
Allergens and rhinovirus infections are among the most common elicitors of respiratory diseases. We report the construction of
a recombinant combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived VP1, the surface protein
which is critically involved in infection of respiratory cells, and a nonallergenic peptide of the major grass pollen allergen Phl p
1. Recombinant hybrid molecules consisting of VP1 and a Phl p 1-derived peptide of 31 aa were expressed in Escherichia coli. The
hybrid molecules did not react with IgE Abs from grass pollen allergic patients and lacked allergenic activity when exposed to
basophils from allergic patients. Upon immunization of mice and rabbits, the hybrids did not sensitize against Phl p 1 but induced
protective IgG Abs that cross-reacted with group 1 allergens from different grass species and blocked allergic patients’ IgE
reactivity to Phl p 1 as well as Phl p 1-induced basophil degranulation. Moreover, hybrid-induced IgG Abs inhibited rhinovirus
infection of cultured human epithelial cells. The principle of fusing nonallergenic allergen-derived peptides onto viral carrier
proteins may be used for the engineering of safe allergy vaccines which also protect against viral infections. The Journal of
Immunology, 2009, 182: 6298–6306.
A ccording to the World Health Organization, asthma be-longs to one of the most severe and disabling diseases(1). Allergens and respiratory viruses are among the
most common environmental factors implicated in the pathogen-
esis of asthma (2). More than 25% of the population suffers from
IgE-mediated allergies and 30% of patients suffering from per-
sistent allergic rhinitis also suffer from asthma (3). The link be-
tween upper and lower airway diseases is also underlined by the
fact that patients suffering from untreated allergic rhinoconjuncti-
vitis frequently develop asthma bronchiole (4). In this context, it
has been shown that allergen exposure via the nasal and respiratory
mucosa induces strong rises of allergen-specific IgE levels, which are
responsible for increased allergen sensitivity in the target organs of
allergy (5). In addition, several studies highlight the importance of
rhinovirus infections in the context of allergic asthma (6, 7).
Human rhinoviruses (HRV)3 have been identified in the late
1950s and early 1960s as the cause of the common cold in the
upper respiratory tract. With the use of PCR-based technology,
HRV have been identified in 60–90% of acute exacerbations of
asthma in children and adults (6). Rhinoviruses are not only a
major cause of asthma exacerbations (8) but allergic individuals
suffer also more often and prolonged from rhinovirus infections in
the lower respiratory tract (9). Furthermore, there is evidence for a
deficient innate immune response (i.e., a deficient-type III IFN-
production) to rhinovirus infections in asthmatic individuals (10).
To date, no effective vaccines or antiviral therapies have been ap-
proved for either the prevention or the treatment of HRV infection.
However, for allergic diseases, allergen-specific immunotherapy is
available as an allergen-specific and disease- modifying form of al-
lergy treatment (11). It is effective for the treatment of allergic asthma
and prevents the progression of allergic rhinoconjunctivitis to allergic
asthma (12). Due to the rapid progress made in the field of allergen
characterization, several new forms of allergen-specific immu-
notherapy have been developed and entered in clinical trials in
allergic patients (reviewed in Refs. 11, 13, and 14).
According to the sequences of major allergens, synthetic pep-
tides containing T cell epitopes without IgE reactivity have been
identified with the aim to induce tolerance in allergen-specific T
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cells (15). DNA-based vaccination has been shown to redirect al-
lergic immune responses in experimental animal studies and CpG-
coupled allergens have been used to modulate the immune re-
sponses and were used for immunotherapy of ragweed allergic
patients (16–18). Furthermore, recombinant allergens and geneti-
cally engineered allergen derivatives with reduced allergenic ac-
tivity have been used for allergy vaccination of allergic patients
(reviewed in Ref. 19).
In this study, we report the development of a novel type of
vaccine for the combined treatment of allergen- and rhinovirus-
induced asthma. The active ingredient of this vaccine is a fusion
protein consisting of the rhinovirus-derived VP1 surface protein
(20, 21) and a hypoallergenic peptide selected from the major grass
pollen allergen Phl p 1 (22). VP1 contains the motifs required for
HRV binding to the target cells and is recognized by HRV-neu-
tralizing Abs (20, 21). The Phl p 1 peptide is located at the Phl p
1 C terminus which contains the majority of IgE epitopes recog-
nized by patients’ IgE but lacks allergenic activity (22, 23). The
fusion protein was thus expected to induce IgG Abs which block
allergic patients’ IgE recognition of the Phl p 1 allergen and to
inhibit HRV infection.
In this study, we report the construction, expression, and puri-
fication of the VP1 fusion protein. We demonstrate the lack of
allergenic activity of the fusion protein using allergic patients’ IgE
and their blood basophils. Furthermore, we show that IgG Abs
obtained after immunization of animals with the fusion protein
inhibit allergic patients’ IgE binding to the Phl p 1 allergen, aller-
gen-induced basophil degranulation, and protect against HRV in-
fection of cultured human cells.
Materials and Methods
Allergic patients, allergen extracts, recombinant allergens,
synthetic peptides, and peptide conjugates
Sera were obtained from patients allergic to grass pollen as confirmed by
case history, skin prick testing, and measurement of specific IgE Abs and
are numbered consistently in the manuscript (22). Pollen from different
grass and corn species (Phleum pratense: Timothy grass; Secale cereale:
rye; Poa pratensis: Kentucky bluegrass; Phragmites australis: Australian
reed; Triticum sativum: cultivated wheat; Lolium perenne: rye grass; Avena
sativa: cultivated oat; Anthoxanthum: sweet vernal grass) were purchased
from Allergon. Natural grass pollen extracts were prepared as described
previously (24). Purified recombinant rPhl p 1 was obtained from Biomay.
The Phl p 1-derived peptide P5 CVRYTTEGGTKTEAEDVIPEG
WKADTAYESK was synthesized and coupled to keyhole limpet hemo-
cyanin (KLH) as described previously (22).
Construction of vector pVP1
Virus stocks of strains HRV89 and 14 were obtained from the collection at
the Institute of Virology, Medical University of Vienna. Viral RNA was
prepared from cell culture supernatants using the QIAamp viral RNA kit
(Qiagen) and RNase inhibitor (Boehringer Mannheim) was added to a final
concentration of 0.01 U/l. The VP1 cDNA was amplified by RT-PCR
using a SuperScript One-Step RT-PCR kit from Invitrogen using the fol-
lowing primers: 5-CGGAATTCATTAATATGAACCCAGTTGAAAAT
TATATAGATAGTGTATTA-3 and 5-CGATTAATTCAGTGGTGGTG
GTGGTGGTGGACGTTTGTAACGGTAA-3. The restriction sites
(EcoRI, AseI) are underlined. The VP1 cDNA was subcloned into the NdeI
and EcoRI sites of the plasmid pET 17b and transformed into Escherichia
coli BL21 DE3 from Novagen (Merck Bioscience) for protein expression.
The DNA sequence of the construct was confirmed by nucleotide sequenc-
ing (MWG) (25).
To allow the insertion of cDNAs coding for unrelated peptides at the 5
end of the VP1-encoding cDNA, the plasmid construct was modified by
changing the CATAAT site which resulted from the subcloning of the AseI
ends of the cDNA into the NdeI site of the vector into an AflII site (CTT
AAG) by site-directed mutagenesis using a Quick Change Site Mutagen-
esis kit (Stratagene) and the primers AflII forward, 5-CTTTAAGAAGGA
GATATACTTAAGATGAACCCAGTTG-3 and AflII reverse, 5-CAA
CTGGGTTCATCTTAAGTATATCTCCTTCTTAAAG-3. Next, the
primers AgeI forward, 5-CCTGATGTTTTTACCGGTACAAACGTCC
ACCAC-3 and AgeI reverse, 5-GTGGTGGACGTTTGTACCGGTAAA
AACATCAGG-3 were used to introduce an AgeI site before the last three
codons of the VP1-encoding cDNA to allow the insertion of cDNAs coding
for peptides at the 3 end. The resulting plasmid was designated pVP1 (Fig.
1a and supplemental Fig. 14).
Construction of plasmids expressing a VP1-P5 and a VP1-2xP5
hybrid protein
A recombinant hybrid protein (VP1-P5) consisting of VP1 and the Phl p
1-derived peptide P5 fused to the VP1 N terminus was obtained by PCR
amplification of a P5-encoding cDNA using forward 5- CGCGCTTAAG
ATGGTCCGCTACACCACCGAGGGC-3 and reverse 5-CGCG
CTTAAGCTTGGACTCGTAGGCGGTGTCGGC-3 primers and the Phl
p 1-encoding cDNA as a template.
The P5-encoding cDNA was inserted into the AflII restriction site of the
pVP1 vector. The resulting construct was further modified by insertion of
a P5-encoding cDNA into the AgeI site at the 3 end of the VP1-encoding
cDNA to yield a hybrid consisting of VP1 with a N-terminal and a C-
terminal P5 peptide designated VP1-2xP5.
Expression and purification of VP1, VP1-P5, and VP1-2xP5
Recombinant VP1, VP1-P5, and VP1-2xP5 were expressed in E. coli
BL21(DE3) and purified from the inclusion body fraction after solubiliza-
tion in 6 M guanidinium hydrochloride, 100 mM NaH2PO4, and 10 mM
Tris (pH 8) using a Ni-NTA affinity matrix (Qiagen). Elution was per-
formed at pH 3.5. Protein preparations were dialyzed against H2Odd and
checked for purity by SDS-PAGE and Coomassie blue staining Mem-
branes containing purified VP1, VP1-P5, and VP1-2xP5 were exposed to a
monoclonal mouse anti-His tag Ab (Dianova). Bound Abs were detected
with alkaline phosphatase-coupled rabbit anti-mouse Abs (BD
Pharmingen).
Allergic patients’ IgE reactivity to the fusion proteins and
basophil activation
Allergic patients’ IgE reactivity to Phl p 1, VP1-P5, VP1-2xP5, or human
serum albumin (HSA) was measured by ELISA as described elsewhere
(26). Sera from three nonallergic individuals were tested as negative con-
trols. The coating of the test Ags to the ELISA plates was confirmed with
specific Ab probes. The allergenic activity of the VP1 fusion proteins was
compared with that of the Phl p 1 allergen by in vitro basophil activation
tests. For this purpose, peripheral blood was obtained from three grass
pollen allergic patients after informed consent was obtained. Basophil ac-
tivation in heparinized whole blood samples and flow cytometric measure-
ment of CD203c expression was performed as previously described (27). In
brief, blood aliquots (100 l) were incubated with serial dilutions of rPhl
p 1, VP1-2xP5 (0.05–50 pM), anti-IgE Ab (1 g/ml, E-124-2-8 D ; Im-
munotech), or buffer alone (PBS). Allergen-induced up-regulation of
CD203c as determined by flow cytometry with PE-conjugated mAb 97A6
(CD203c) was calculated from mean fluorescence intensities (MFIs) ob-
tained with stimulated (MFIstim) and unstimulated (MFIcontrol) cells and
was expressed as stimulation index (SI  MFIstim:MFIcontrol) (27).
Immunization of mice and rabbits, reactivity of mouse and
rabbit Abs with VP1 and Phl p 1, and demonstration of
reaginic activity of mouse Abs
Groups of five mice each were immunized three times s.c. with 5 g of P5,
rPhl p 1, VP1, VP1-P5, or VP1-2xP5 adsorbed to aluminum hydroxide in
3-wk intervals and bled from the tail veins. Animals were maintained in the
animal care unit of the Department of Pathophysiology (Medical Univer-
sity of Vienna) according to the local guidelines for animal care (28). The
mouse immunization experiments were repeated three times. Rabbit Abs
specific for VP1, KLH-P5, VP1-P5, and VP1-2xP5 were obtained by im-
munizing rabbits (Charles River). ELISA plates (Nunc Maxisorb) were
coated with 5 g/ml of the Ags and incubated with mouse sera diluted
1/500 as previously described (28, 29). Bound mouse IgG1, IgG2a, or
IgG2b were detected with monoclonal rat anti-mouse IgG1, IgG2a, or
IgG2b Abs (BD Pharmingen) diluted 1/1000, respectively, and then with
goat anti-rat IgG HRP-coupled Abs (Amersham Biosciences) diluted
1/2000. Bound rabbit IgG Abs were detected with 1/2000 diluted donkey
anti-rabbit IgG HRP-coupled Abs (Amersham Biosciences). OD was mea-
sured at 405 and 490 nm in an ELISA reader (Dynatech).
The induction of Phl p 1-specific IgE Abs with allergenic activity was
determined in sera from mice that had been immunized with Phl p 1, VP1-P5,
4 The online version of this article contains supplemental material.
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VP1-2xP5, or VP1 using RBL-2H3 cells. Rat basophil leukemia cells (RBLs)
were loaded with mouse sera and timothy grass pollen extract containing nat-
ural Phl p 1 allergen (5 g/ml) or VP1 as described elsewhere (30).
Proliferation of mouse spleen cells and cytokine analysis
Spleen cells were prepared from mice that had been immunized four times
with P5, VP1, VP1-P5, KLH-P5, or PBS 10 days after the last immuniza-
tion. Spleen cell cultures from each mouse were stimulated with P5 (0.26
g/100 l), VP1 (2 g/100 l), Con A (2 g/100 l) (positive control), or
medium alone and after 4 days [3H]thymidine uptake was measured and
displayed as SI as described previously (30). Cytokines were measured
after stimulation of spleen cells with Phl p 1, KLH, VP1, or Con A (15
g/50 l each). IL-4, IL-5, IL-10, TGF-ß, and IFN- levels were measured
by xMAP Luminex fluorescent bead-based technology. The assay was per-
formed according to the manufacturer’s introduction (R&D Systems) and
fluorescence signal was read on a Luminex 100 System (Luminex). Cyto-
kine measurements were done for splenocytes from each mouse for a par-
ticular cytokine. From these values, the assay cutoff level for the given
cytokine was subtracted and this value was normalized to the proliferation
results (SI) according to the formula: (mean cytokine level  cytokine
cutoff)/SI factor. The mean values of the factors were calculated for each
group of mice and each cytokine to allow a comparison among the groups.
Statistics
Differences in Ab and cytokine levels induced by immunization of mice
were determined by the Mann-Whitney U test using SPSS software. A
value of p  0.05 was considered as significant.
Cross-reactivity of anti-VP1-2xP5 Abs with natural group 1
grass pollen allergens
Grass pollen extracts from eight grass species were separated on a 12.5%
SDS-PAGE and blotted onto a nitrocellulose membrane. Identically pre-
pared membranes were incubated with rabbit anti-VP1-2xP5 Abs or the
corresponding preimmune Ig overnight at 4°C and bound IgG Abs were
detected with 125I-labeled donkey anti-rabbit IgG as previously described
(22).
Inhibition of allergic patients’ IgE binding to Phl p 1 and of Phl p
1-induced basophil degranulation with vaccine-induced IgG Abs
The inhibition of allergic patients’ IgE reactivity to Phl p 1 by IgG Abs
which had been raised by immunization of rabbits with the rPhl p 1 aller-
gen, VP1-P5, VP1-2xP5, and a KLH-coupled peptide P5 (22) was mea-
sured by ELISA as described elsewhere (28, 29). In brief, ELISA plates
were coated with 1 g/ml rPhl p 1, washed, and blocked. Then plate-bound
Phl p 1 was preincubated with 1/250 dilutions of specific rabbit Ig or, for
control purposes, of the preimmune Ig. After washing, plates were incu-
bated with 1/3 diluted sera from allergic patients with a RAST class of 3
to timothy grass pollen allergens and bound IgE Abs were detected with
1/1000 diluted alkaline phosphatase-coupled mouse monoclonal anti-
human IgE Abs (BD Pharmingen). The OD corresponding to bound IgE
was measured at 405 and 450 nm. The percentage of inhibition of IgE
binding achieved by preincubation with the anti-peptide antisera was cal-
culated as previously described (28).
The inhibition of Phl p 1-induced basophil degranulation by vaccine-
induced IgG Abs was investigated as follows: RBL-2H3 cells transfected
with human high-affinity IgE receptor (FcR1) (31) were loaded with se-
rum IgE from Phl p 1-allergic patients and then exposed to 100 ng/ml Phl
p 1 that had been preincubated with increasing concentrations (0, 2.5, 5, or
10% v/v) of rabbit Ig raised against Phl p 1 or VP1-2xP5 or the corre-
sponding preimmune Ig. The release of -hexosaminidase was measured as
described previously (31) and is expressed as percentage of total cellular
-hexosaminidase.
HRV neutralization test
The virus stock titer used in the experiment was determined by 50% tissue
culture infectious dose (TCID50) titration on HeLa cells according to the
Spearman-Kaerber method (32).
For the neutralization tests, 300-l aliquots containing a 100 TCID50 of
HRV89 or 14 were preincubated for 2 h at 37°C with 300-l aliquots
(undiluted, 1/2–1/32) of the anti-VP1-P5 or anti-VP1-2xP5 antiserum be-
fore addition to HeLa cells. Infection of HeLa cells with 100 TCID50 of
HRV89 or 14 was performed for control purposes. For control purposes, cells
were incubated with medium alone or immune serum without virus. The cy-
totoxic effect of the virus was visualized with crystal violet after 3 days (33).
Results
Expression and purification of VP1 and of a fusion protein
consisting of VP1 and one or two grass pollen allergen peptides
Plasmid pVP1 (Fig. 1a) was constructed by replacing the NdeI/EcoRI
fragment of the multiple cloning site of pET-17b with the cDNA
sequence encoding the complete VP1 protein of human rhinovirus
strain 89. The NdeI and EcoRI restriction sites (of pET-17b) were
used for insertion of the VP1 cDNA containing AseI and EcoRI sites
at the 5 and 3 end, respectively. An AflII (5 end) and an AgeI (3
end) restriction site were generated at the ends of the VP1-encoding
cDNA by mutagenesis to allow fusion with foreign cDNAs. The AgeI
restriction site was placed between the 3 end of the VP1 cDNA and
a cDNA coding for a C-terminal hexahistidine tag (Fig. 1a and sup-
plemental Fig. 1). Plasmid VP1 thus allows the expression of com-
plete VP1 with a C-terminal hexahistidine tag. In addition, allergen-
derived peptides can be fused to the N and/or C terminus of VP1.
Recombinant VP1 was expressed in E. coli with a C-terminal
hexahistidine tag and purified by nickel affinity chromatography in
a single-step procedure yielding 5 mg of protein/L of culture.
Recombinant VP1 migrates at 34 kDa in SDS-PAGE (Fig. 1b).
Next, we expressed and purified two fusion proteins consisting of
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FIGURE 1. Representation of pVP1, expression and purification of
VP1, VP1-P5, and VP1-2xP5. a, Construction of an expression plasmid
(pVP1) containing the cDNA coding for VP1. The VP1-encoding cDNA
was inserted into the multiple cloning site of plasmid pET17b and an AflII
and AgeI restriction sites were introduced at the 5 and 3 end of the VP1-
encoding cDNA, respectively. b, SDS-PAGE containing purified VP1,
VP1-P5, and VP1-2xP5. Molecular masses in kDa are indicated.
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VP1 and the nonallergenic peptide (P5) derived from the major
Timothy grass pollen allergen Phl p 1. In the fusion protein VP1-
P5, the peptide is fused to the N terminus of VP1 and in the fusion
protein VP1-2xP5 one peptide is attached to the VP1 N and one to
the C terminus. Recombinant VP1-P5 and VP1-2xP5 exhibited a
molecular mass of 37 and 41 kDa, respectively, in SDS-PAGE
(Fig. 1b). Bands below 30 kDa in the recombinant protein prepa-
rations reacted with an anti-His tag Ab and therefore represent
degradation products of the purified recombinant proteins.
VP1-P5 and VP1-2xP5 are nonallergenic fusion proteins
Recombinant VP1-P5 and VP1-2xP5 were compared with the
complete recombinant Phl p 1 allergen regarding IgE reactivity
using sera from 23 grass pollen allergic patients by ELISA (Table
I). Each of the grass pollen allergic patients showed IgE reactivity
to rPhl p 1 (mean OD, 0.837). However, no relevant IgE reactivity
to VP1-P5 or VP1-2xP5 was found. Likewise, no relevant IgE
binding was observed when three nonallergic individuals were
tested for IgE reactivity to the fusion proteins (Table I). No IgE
reactivity to HSA (mean OD, 0.048) could be detected (Table I).
The lack of allergenic activity of VP1-2xP5 was confirmed by
experiments using basophils from grass pollen allergic patients
(Fig. 2). rPhl p 1 and anti-IgE induced the up-regulation of
CD203c on basophils from each of the three grass pollen allergic
patients at concentrations of 0.05 pM, whereas VP1-2xP5 did not
induce any response up to a concentration of 50 pM (Fig. 2).
VP1-P5 and VP1-2xP5 induce a VP1- and grass pollen-specific
Th1-like immune response with lowered Th2 activation
To determine the immunogenicity of VP1 and its ability to act as
a carrier for allergen-derived peptides, groups of mice were im-
munized with the following Ags: P5, rPhl p 1, VP1, VP1-P5, and
VP1-2xP5. VP1- and Phl p 1- specific IgG1 Ab levels were de-
termined by ELISA (Fig. 3). VP1-specific IgG1 Abs were detected
already 3 wk after immunization in mice that had received VP1 or
VP1- containing allergen-derived peptides, but not in mice that had
been immunized with P5 or Phl p 1 (Fig. 3a).
The fusion of the Phl p 1-derived peptide (P5) to VP1 strongly
increased the immunogenicity of P5 because no relevant Phl p
1-specific IgG1 responses were found in mice immunized with P5
alone, whereas VP1-P5 and VP1-2xP5-immunized mice showed
Phl p 1-specific IgG1 responses after 3 wk, which continued to
increase after 6 and 9 wk (Fig. 3b). The Phl p 1-specific IgG1
responses in the latter two groups of mice were even of compara-
ble magnitude to the IgG1 responses induced by immunization
with the complete Phl p 1 allergen. Immunization with VP1 alone
did not induce any Phl p 1-specific immune response (Fig. 3b).
VP1-P5 and VP1-2xP5 induced IgG2a and IgG2b responses to Phl
p 1. No Phl p 1-specific IgG2 responses were found in P5- and VP1-
immunized mice (Fig. 3b). Interestingly, VP1-specific IgG2a and
IgG2b responses were significantly stronger ( p  0.05) in the VP1-
immunized mice as compared with the mice having received VP1-P5
or VP1-2xP5, indicating that VP1 contributes to the Th1 component
of the immune responses whereas the allergen-derived peptides
seemed to reduce this activity (Fig. 3a). To determine the specificity
of T cell responses, spleen cells from immunized mice were exposed
to P5, VP1, or to culture medium alone (Fig. 4, x-axes). Spleen cells
from VP1-immunized mice showed proliferation (SI 6) to VP1 but
no relevant proliferation to P5 or to medium alone. Spleen cells from
VP1-P5-immunized mice that had developed IgG responses against
Phl p 1 did not show relevant proliferation to P5 but responded
strongly (SI  6) to VP1, indicating that the Phl p 1-specific IgG
responses had received VP1-specific T cell help (Fig. 4). P5-immu-
nized mice did not show any relevant proliferation similar to cells
from a nonimmunized mouse (Fig. 4). Spleen cells from VP1-P5-
immunized mice did not release relevant levels of IL-5, whereas a
stronger secretion of IL-5 was found in culture supernatants from
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FIGURE 2. Activation of human basophils. Blood of three grass pollen allergic patients (patients 8, 11, and 23) were stimulated with PBS (Co), anti-IgE,
serial dilutions (0.05, 0.5, 5, and 50 pM) of Phl p 1 (f) or VP1–2xP5 (u) (x-axes). CD203c expression is displayed as SI (y-axes).
Table I. IgE reactivity to HSA, Phl p 1, VP1-P5, and VP1-2xP5a
Patient
IgE Reactivity of Allergic
Patients’ Sera
HSA Phl p 1 VP1-P5 VP1-2xP5
1 0.056 0.235 0.077 0.087
2 0.046 0.586 0.061 0.066
3 0.049 0.9 0.059 0.057
4 0.07 1.031 0.061 0.059
5 0.016 0.889 n.d. 0.178
6 0.044 0.308 0.044 0.051
7 0.054 0.605 0.05 0.046
8 0.047 0.476 0.052 0.055
9 0.045 0.151 0.045 0.045
10 0.061 0.288 0.048 0.047
11 0.048 1.879 0.059 0.061
12 0.059 1.638 n.d. 0.092
13 0.051 2.098 0.048 0.046
14 0.064 0.166 0.044 0.046
15 0.05 0.697 0.059 0.048
16 0.058 1.864 0.079 0.069
17 0.053 1.39 0.053 0.048
18 0.046 1.062 0.045 0.045
19 0.045 0.845 0.059 0.056
20 0.008 0.4 n.d. 0.099
21 0.048 0.397 0.058 0.057
22 0.045 0.24 n.d. 0.02
23 0.051 1.117 0.056 0.058
Mean 0.048 0.837 0.056 0.062
24 0.048 0.052 0.051 0.047
25 0.042 0.043 0.05 0.044
26 0.043 0.048 0.048 0.044
a Serum IgE reactivity to the purified Ags was determined by ELISA and is dis-
played as mean OD values of duplicate measurements for sera from 23 grass pollen
allergic patients. Mean OD values for the 23 sera and each antigen are indicated in
bold.
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spleen cells of mice that had been immunized with KLH-P5 (Fig. 4).
No relevant differences regarding the production of IL-10, IL-4, and
TGF-ß were found between the different groups (Fig. 4).
VP1-2xP5 does not induce an allergenic immune response
against Phl p 1 or against VP1
To study whether immunization with the various Ags (Phl p 1,
VP1, VP1-P5, VP1-2xP5) induces reaginic IgE Abs, RBLs were
loaded with sera from immunized mice and exposed to pollen-
derived Phl p 1 or VP1 (Fig. 5). Immunization with Phl p 1 but not
with VP1 or the VP1-P5 constructs induced reaginic Abs which
lead to degranulation of RBLs in response to timothy grass pollen-
derived Phl p 1 (Fig. 5, Timothy grass pollen extract). Interest-
ingly, neither immunization with VP1, VP1-P5, nor VP1-2xP5 in-
duced IgE Abs which caused degranulation of RBLs in responses
to the VP1 protein (Fig. 5, VP1).
FIGURE 3. Immune responses of
immunized mice. a–f, Phl p 1- and
VP1-specific IgG1 and IgG2 re-
sponses. Mice were immunized with
P5, Phl p 1, VP1, VP1-P5, and VP1-
2xP5 (top boxes). Serum samples
were taken on the day of the first im-
munization (0) and in 3-wk intervals
(3w–9w) (x-axes). IgG1 and IgG2 re-
activities are displayed for each
mouse group as box plots, where 50%
of the values are within the boxes and
nonoutliers between the bars. The
lines within the boxes indicate the
median values. IgG1, IgG2a, and
IgG2b levels specific for VP1 (a) and
Phl p 1 (b) are displayed as OD values
(x-axes). IgG2a (c) and IgG2b (d) lev-
els specific for Phl p 1 and IgG2a (e)
and IgG2b (f) levels specific for VP1
are displayed as OD values (y-axes).
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Immunogen IL-10 IL-4 IL-5 IFN-γ TGF-ß 
KLH-P5 3.3 0 30.2 0 0.4 
VP1-P5 1.7 0 0 0 0.2 
PBS 7.1 0 0.4 0 0.8 
FIGURE 4. T cell responses of immunized mice.
The lymphoproliferative responses (y-axes: SI 
SD) of immunized mice (top of the boxes: immu-
nogens) and a nonimmunized (Co) mouse stimu-
lated with medium alone (M), P5, or VP1 (x-axes)
are displayed. The table shows the levels of IL-10,
IL-4, IL-5, IFN-, and TGF-ß in Phl p 1-stimulated
spleen cell cultures after normalization to the pro-
liferations results (i.e., cytokine level/SI) in groups
of mice immunized with different immunogens
(KLH-P5, VP1-P5) or buffer (PBS).
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Anti-VP1-2xP5 Abs cross-react with natural group 1 pollen
allergens from several grass species
To study whether IgG Abs induced with the hybrid proteins cross-
react with natural group 1 allergens from several grass species,
immunoblot experiments were performed. Fig. 6a shows that rab-
bit anti-VP1-2xP5 Abs strongly bound to natural Phl p 1 in P.
pratense pollen and to natural group 1 allergens in pollen from
several other grass species including P. pratensis, L. perenne, and
Anthoxanthum odoratum. A distinct but weaker reactivity to group
1 allergens from P. australis, A. sativa, T. aestivum, and S. cereale
were found (Fig. 6a). No IgG reactivity to the pollen allergens was
found when an identically prepared blot was exposed to the rab-
bit’s preimmune serum (Fig. 6b).
VP1-2xP5-specific Abs inhibit allergic patients’ IgE binding to
Phl p 1 and Phl p 1-induced basophil degranulation more
efficiently than Abs raised against the complete allergen
Serum IgE Abs from 18 grass pollen allergic patients were allowed
to bind to Phl p 1 which had been preincubated with anti-Phl p 1,
anti-KLH-P5, anti-VP1-P5, or anti-VP1-2xP5 Abs (Table II). Abs
raised against the complete Phl p 1 allergen showed a rather weak
inhibition of IgE reactivity ranging from 0 to 45%. A stronger
inhibition of IgE reactivity was obtained with Abs raised against
VP1-P5 (13–68%; mean inhibition 39%) and Abs raised against
KLH-coupled P5 (7–70%; mean inhibition 47%; Table II). The
strongest inhibition of allergic patients’ IgE reactivity was ob-
tained with Abs raised against the VP1-2xP5 construct ranging
from 29 to 91%, with a mean inhibition of 63% (Table II).
The much stronger inhibition of patients’ IgE reactivity of Phl p
1 by anti-VP1-2xP5 Abs compared with anti-Phl p 1 Abs may be
explained by the higher titer of the anti-VP1-2xP5 IgG compared
with the anti-Phl p 1 IgG (Table III).
Similar results were obtained when anti-VP1-2xP5 Abs were
studied for their capacity to inhibit Phl p 1-induced degranulation
of RBLs that had been loaded with IgE from four grass pollen
allergic patients (Fig. 7). The anti-VP1-2xP5 antiserum started to
inhibit Phl p 1-induced basophil degranulation already at a con-
centration of 2.5% and caused a 50% inhibition of degranulation
at a concentration of 10% (Fig. 7). The Phl p 1-specific Abs caused
a much weaker inhibition of Phl p 1-induced degranulation, which
became detectable only at a concentration of 10%.
VP1-specific Abs inhibit HRV89 infection of HeLa cells
Next, we were interested to investigate whether VP1-specific IgG
Abs can inhibit human rhinovirus infection of HeLa cells. Results
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FIGURE 5. Reduced allergenicity of VP1-P5 and VP1-2xP5 vs Phl p 1.
RBLs were loaded with sera from immunized mice (Immunogens: bottom
of the boxes) and incubated either with natural Phl p 1 (Timothy grass
pollen extract) or VP1 (top of the boxes). The ß-hexosaminidase releases
are displayed as percentages of total releases for each mouse group as box
plots, where 50% of the values are within the boxes and nonoutliers be-
tween the bars. The lines within the boxes indicate the median values.
FIGURE 6. Cross-reactivity of anti-VP1-2xP5 Abs with natural group 1
grass pollen allergens. Nitrocellulose-blotted pollen extracts from eight
grasses (nos. 1–8: P. pratense, P. australis, A. sativa, P. pratensis, T.
sativum, S. cereale, L. perenne, A. odoratum) were incubated with rabbit
anti-VP1-2xP5 Abs (a) or the corresponding preimmune serum (b). Mo-
lecular masses are displayed on the left margin in kDa.
Table II. Inhibition of grass pollen allergic patients’ IgE binding to
Phl p 1 with IgG Absa
Patient
Inhibition of IgE binding (%)
Anti-Phl p 1 Anti-KLH-P5 Anti-VP1-P5 Anti-VP1-2xP5
1 1 13 13 31
2 0 51 19 66
3 27 49 36 65
4 16 46 40 71
5 14 55 39 57
6 13 35 24 55
7 18 37 26 61
8 29 55 24 72
9 17 51 41 64
10 9 46 31 65
11 0 64 50 67
12 0 55 28 88
13 14 55 50 91
14 0 7 32 29
15 11 56 58 58
16 45 70 68 74
17 28 58 55 72
18 24 41 50 36
Mean 15 47 39 63
a The inhibitions of allergic patients’ (nos. 1–18) IgE binding by anti-Phl p 1,
anti-KLH-P5, anti-VP1-P5, or anti-VP1-2xP5 Abs to ELISA plate-bound Phl p 1 are
expressed as percentages of inhibition using the preimmune Abs as reference. Mean
inhibitions for the group of 18 patients are displayed in the bottom line.
Table III. Titration of rabbit anti-Phl p 1 and anti-VP1-2xP5 IgG Absa
Serum
Dilution
IgG Reactivity to HSA, Phl p 1, and VP1-2xP5
Anti-Phl p 1 Anti-VP1-2xP5
HSA Phl p 1 VP1-2xP5 HSA Phl p 1 VP1-2xP5
1/10,000 0.003 0.493 0.116 0.000 0.914 1.438
1/20,000 0.000 0.454 0.063 0.000 0.835 1.476
1/50,000 0.000 0.075 0.026 0.044 0.332 0.903
1/100,000 0.000 0.117 0.020 0.018 0.281 0.885
a Different serum dilutions of rabbit anti-Phl p 1 and rabbit anti-VP1-2xP5 were
tested for reactivity to HSA, Phl p 1, or VP1-2xP5. OD values correspond to bound
IgG Abs.
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from a representative experiment performed with a HRV89 strain
are shown in Fig. 8. When cells were infected with of 100 TCID50
of HRV89, a complete cytopathic effect was observed (Fig. 8, row
C, well 1). Addition of VP1-P5- as well as VP1-2xP5-specific Abs
prevented HRV-induced cell death up to a dilution of the VP1-
specific antiserum of 1/32 (Fig. 8, rows A and B). Cells incubated
in medium without virus were fully alive (Fig. 8, row C, wells 2
and 3). Addition of antisera to the noninfected cells showed no
relevant effects (Fig. 8, row C, wells 4–6). Similar results with
anti-VP1 Abs were obtained when another rhinovirus strain
(HRV14) was used instead of HRV89 (data not shown).
Discussion
Allergens and rhinovirus infections are among the most common
triggers of asthma. To develop a vaccine which would confer pro-
tective immunity against rhinovirus infections as well as against
allergies, we constructed an expression plasmid that allows the
expression and purification of chimeric proteins consisting of rhi-
novirus-derived VP1 and allergen-derived peptides. VP1 was se-
lected because it is the HRV-derived surface protein that is criti-
cally involved in rhinovirus infection of human cells, shows a high
degree of sequence homology among various rhinovirus strains,
and is recognized by Abs neutralizing rhinovirus infections
(34, 35).
The VP1-based allergy vaccine was designed to minimize the
risk of inducing IgE- and T cell-mediated side effects during ther-
apy. For the reduction of IgE-mediated side effects, allergen-de-
rived peptides without IgE reactivity, as represented by the Phl p
1-derived peptide can be selected according to B cell epitope map-
ping data, prediction of surface-exposed areas using computer pro-
grams, or according to the three-dimensional allergen structures
(22, 29). When coupled to a foreign carrier molecule and used for
immunization, these peptides induce robust allergen-specific IgG
responses, which block IgE recognition of the allergen and IgE-
mediated allergic inflammation. The peptides can be further se-
lected to minimize the presence of frequently recognized allergen
T cell epitopes to reduce T cell-mediated side effects as have been
described in clinical trial performed with non-IgE-reactive T cell
epitope peptides (36). The carrier principle is based on classical
work performed by Benacerraf and colleagues (37–39) who stud-
ied the mechanisms underlying Ab production against small hap-
tens that have been coupled to carriers. Their work has demon-
strated that Ab responses can be obtained against haptens when
they are coupled to unrelated carrier molecules that are recognized
by T lymphocytes.
The VP1-based vaccine for the major timothy grass pollen al-
lergen exemplifies the possible beneficial features of a combined
vaccine for allergy and rhinovirus infections that is based on small
allergen-derived peptides that are coupled to carrier molecules de-
rived from viruses.
Recombinant VP1-P5 and rVP1-2xP5 lack IgE reactivity and
allergenic activity. Therefore, the vaccine should induce little or no
IgE-mediated side effects in allergic patients. Immunization of
mice and rabbits showed that the proteins induced allergen-specific
IgG responses which inhibited allergic patients’ IgE binding to the
complete Phl p 1 allergen and Phl p 1-induced immediate allergic
inflammation as demonstrated by the inhibition of basophil de-
granulation. Interestingly, VP1-2xP5-induced IgG Abs inhibited
allergic patients’ IgE recognition of Phl p 1 much stronger than
those IgG Abs induced by immunization with the complete Phl p
1 allergen, suggesting that the VP1-based vaccine should be more
effective than currently existing vaccines containing the Phl p 1
allergen. IgG Abs induced with the VP1-based vaccine cross-re-
acted with group 1 allergens from several common grasses, indi-
cating that the vaccine should be also useful to treat allergies to
various grasses. A National Center for Biotechnology Information
BLAST search with the P5 amino acid sequence demonstrated in
fact a close relation of the timothy grass-derived peptide with ho-
mologous peptides from L. perenne, P. pratensis, T. aestivum, and
A. odoratum which also reacted strongly with the VP1-2xP5-in-
duced IgG Abs. Vaccination of one healthy volunteer has shown
that the VP1-based vaccine also induces allergen-specific and rhi-
novirus-specific immune responses in humans (data not shown).
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FIGURE 7. Inhibition of IgE-mediated basophil degranulation by VP1-
2xP5-specific IgG Abs. RBLs transfected with the human FcRI were
loaded with IgE from different grass pollen allergic patients (left margin,
nos. 1–4 and 19) and exposed to Phl p 1 along with increasing concen-
trations of rabbit anti-Phl p 1 or anti-VP1–2xP5 antiserum or the preim-
mune serum in the presence of Phl p 1 (X-axes: percentages, v/v, of rabbit
antisera). ß-Hexosaminidase releases are displayed as percentages of total
ß-hexosaminidase contents of the cells (y-axes).
FIGURE 8. VP1-specific Abs inhibit HRV89 infection of HeLa cells.
HeLa cells were seeded in a tissue culture plate at equal density per well.
In rows A and B, cells were infected with the 100-fold dose of HRV89 that
had left 50% of cells intact (100 TCID50). Viral infection was performed in
the presence of serial dilutions of anti-VP1-P5 Abs (undiluted, 1/2–1/32
wells 1–6) (row A) or serial dilutions of anti-VP1–2xP5 Abs (row B). Well
1 in row C was incubated with 100 TCID50, wells 2 and 3 with medium
alone, and wells 4–6 with the Abs alone (well 4, anti-VP1; well 5, anti-
VP1-P5; well 6, anti-VP1-2xP5). Intact cells were stained with a violet dye.
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Unfortunately, the efficacy of prophylactic or therapeutic applica-
tion of our vaccine in a purely mouse-based model could not be
studied because the murine IgE response is directed against dif-
ferent IgE epitopes than that of Phl p 1-allergic patients. However,
the VP1-based allergy vaccine has induced in animals IgG Abs
that blocked allergic patients’ IgE recognition of the allergen.
Thus, similar data have been obtained for the VP1-based vaccine
as for other hypoallergenic allergen derivatives that have already
been successfully applied in patients in clinical trials (40, 41).
Grass pollen also include other important allergens besides the
group 1 allergen represented by Phl p 1, but it has been shown that
a mixture of only four allergens, i.e., Phl p 1, Phl p 2, Phl p 5, and
Phl p 6, was sufficient to treat grass pollen allergy (42). At present,
we have identified hypoallergenic peptides from the latter three
allergens and it should therefore be feasible to construct a VP1-
based grass pollen vaccine using the approach described in this
study.
As another possibly advantageous feature of the VP1-based vac-
cine, we noted that the VP1 portion of the hybrid vaccine seemed
to drive the immune response toward Th1 because we observed
higher Phl p 1-specific IgG2 Ab levels and lower levels of IL-5 in
VP1-P5- and VP1-2xP5- immunized mice compared with Phl p
1-immunized mice.
The VP1-based grass pollen vaccine induced mainly VP1-spe-
cific T cell responses but no allergen-specific T cell responses
could be detected. We therefore assume that the T cell help for the
allergen-specific IgG response induced by the vaccine comes from
VP1-specific T cells. It is therefore likely that the VP-based allergy
vaccines will induce little or no side effects through stimulation of
allergen-specific T cells and thus be superior to recombinant hy-
poallergenic allergen derivatives which still can elicit T cell acti-
vation (43) and also induced late-phase side effects when injected
into patients (44).
Furthermore, it may be expected that the VP1-based vaccine
does not induce allergen-specific T cell responses or allergic sen-
sitization and therefore should be suited for prophylactic applica-
tions. Support for this assumption comes from our finding that the
VP1-based vaccines did not induce reaginic Phl p 1-specific IgE
Abs upon immunization, whereas the complete natural Phl p 1
allergen primed strong reaginic Phl p 1-specific IgE responses.
Finally, we found that the VP1-based vaccine gave rise to VP1-
specific Abs which inhibited the rhinovirus infection of human
HeLa cells. In fact, we have demonstrated that Abs induced with
HRV89-derived VP1 not only protected against HRV89 infections
but also against infections caused by a distantly related rhinovirus
strain such as HRV14 (data not shown).
VP1-based allergy vaccines may therefore be useful for therapy
and prevention of asthma caused by allergens and rhinovirus
infections.
Disclosures
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Cigarette smoke facilitates allergen penetration across respiratory
epithelium
Smoking is one of the environmental factors thought to
have an impact on allergic diseases (1). Both allergic disease
and smoking have an extremely high prevalence: it has been
estimated that more than 25% of the population of
industrialized countries suﬀer from IgE-mediated allergies,
with a continuous tendency to increase (2). The prevalence
of smoking is 20.9% in the adult population in theUSA (3)
and even higher in many European countries (4). Allergic
patients suﬀering from airway disease tend to quit smoking
in order to improve airway function (5, 6), but nevertheless
there is a huge number of allergic individuals who are also
cigarette smokers. Whether cigarette smoking has an
impact on the development and course of allergy is a
controversial matter.
Several epidemiological studies suggest a positive
association between smoking and allergy. For example,
Background: The association between cigarette smoke exposure and allergic
airway disease is a matter for debate. We sought to investigate in an in vitro
system whether active smoking reduces the integrity and barrier function of the
respiratory epithelium and thus facilitates allergen penetration.
Methods: We cultured the human bronchial epithelial cell line 16HBE14o) in a
transwell culture system as a surrogate for the intact respiratory epithelium.
The cell monolayer was exposed to standardized cigarette smoke extract (CSE).
The extent and eﬀects of trans-epithelial allergen penetration were measured
using 125I-labelled puriﬁed major respiratory allergens (rBet v 1, rPhl p 5 and
rDer p 2) and histamine release experiments.
Results: Exposure of cells to concentrations of CSE similar to those found in
smokers induced the development of para-cellular gaps and a decrease in trans-
epithelial resistance. CSE exposure induced a more than threefold increase in
allergen penetration. Increased subepithelial allergen concentrations provoked a
substantial augmentation of histamine release from sensitized basophils.
Conclusions: Our results indicate that cigarette smoke is a potent factor capable
of reducing the barrier function of the respiratory epithelium for allergens and
may contribute to increased allergic inﬂammation, exacerbation of allergic
disease and boosting of IgE memory.
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elevated levels both of total and speciﬁc IgE have been
found in smokers and in asthmatic smokers (7–9).
Smoking has also been identiﬁed as a risk factor for
sensitization to house dust mite allergens (10) and for the
development of occupational sensitization towards sev-
eral environmental allergens (11, 12). However, several
other epidemiological studies report a negative associa-
tion between active smoking and atopy (2, 5, 13).
Yet, passive smoke exposure in children through
parental smoking has been shown to be associated with
an increased risk of allergic sensitization later in life (14,
15). A recent meta-analysis of studies on occupational
exposure indicated that smoking may promote IgE-
mediated sensitization and development of airway dis-
eases (16). The latter observation gains support from
experimental studies performed in mice which show that
smoke-exposed mice mount higher allergen-speciﬁc IgE
levels and develop more severe allergen-induced lung
inﬂammation than mice without smoke exposure (17–19).
In already sensitized allergic patients inhalation of
tobacco smoke induced an increase in allergen-speciﬁc
IgE in nasal lavage ﬂuids when patients were exposed to
respiratory allergens (20).
In this study, we investigated whether cigarette smoke
can directly impair the barrier function of the respiratory
epithelium for allergens which would provide an explana-
tion for the observations that cigarette smoke promotes
sensitization to allergens, allergen-induced allergic inﬂam-
mation and boosting of IgEmemory responses. It has been
shown that cigarette smoke has a direct inﬂuence on
respiratory epithelial and alveolar cells (21–25). In this
study we investigated how smoking aﬀects the penetration
of deﬁned allergens through the respiratory epithelium.
For this purpose, we used a bronchial epithelial cell line
as a surrogate for the intact respiratory epithelium and
several puriﬁed important respiratory allergens in a two-
chamber transwell system to investigate the impact of
cigarette smoke on respiratory barrier function for
allergens as well as on allergen-induced release of
inﬂammatory mediators from co-cultured basophils.
Methods
Culture of human bronchial epithelial cell layers
An epithelial cell line (16HBE14o)) derived from human bronchial
epithelial cells was grown in cell layers (26). These cells can be used
as a surrogate for the respiratory epithelium because they grow in
polarized monolayers and retain properties of diﬀerentiated airway
epithelial cells, form tight junctions, apical microvilli and cilia and
exhibit regulated ion transport.
16HBE14o) cells were grown in minimal essential medium
(Gibco, Carlsbad, CA, USA) containing 10% foetal calf serum
(Gibco), 100 U/ml penicillin (Gibco), 100 lg/ml streptomycin
(Gibco) and 2 mM glutamine (Gibco) and were passaged when
reaching approximately 75–85% conﬂuence. For barrier function
experiments, cells were plated at a density of 2 · 105 per 500 ll of
medium to the upper chamber of 12-mm-diameter transwell inserts
(polyester membranes, 0.4 lm pore size; Costar, Cambridge, MA,
USA). The upper chamber was ﬁlled with 500 ll of medium and the
lower chamber was ﬁlled with 1500 ll of medium.
Preparation of aqueous cigarette smoke extract
A cigarette smoking machine which was previously described was
used for the production of aqueous cigarette smoke extract (CSE)
(27, 28). In short, CSE was produced by consecutively bubbling the
smoke of two commercially available ﬁlter cigarettes (Marlboro;
Philip Morris International Inc., New York, NY, USA; nicotine:
0.8 mg; tar 10 mg) through 8 ml of minimal essential medium
(Gibco) containing 100 U/ml penicillin (Gibco), 100 lg/mL strep-
tomycin (Gibco) and 2 mM glutamine (Gibco) (27, 28). Cigarettes
were machine smoked at a rate of 15 ml/s for 2 s followed by a
pause of 28 s, mimicking the smoking habits of an average smoker
(29). The contents of the CSE produced in this setting have been
standardized to contain a nicotine concentration of 44 ng nicotine/
ml CSE (28) which is comparable with plasma nicotine concentra-
tions of smokers (43.7 ± 38 ng/ml) (30). The dilutions used in this
study (2–32% of the CSE produced in the machine) were in the
range of 14.1 (32%) to 0.9 (2%) ng nicotine/ml.
Examination of cell monolayers by using phase contrast microscopy
Cells were cultured in 25-cm2 tissue culture ﬂasks. When cells were
conﬂuent, medium was changed and cells were incubated with dif-
ferent concentrations of CSE (2%, 4%, 8%, 16% and 32%) or
medium alone at 37C in a humidiﬁed atmosphere containing 5%
CO2. After 3 h of incubation, cells were examined with a phase con-
trast microscope (Zeiss Axiovert 40C, Zeiss, Oberkochen, Germany)
and photographed with a camera mounted on the microscope.
Measurement of trans-epithelial resistance under the influence
of different concentrations of cigarette smoke extract
Epithelial barrier function was determined by measuring trans-
epithelial resistance (TER) using an ohmvoltmeter (Millipore,
Bedford, MA, USA). Baseline resistance across polyester mem-
branes without cellular monolayers was 100 X/cm2 on average. The
respective values were subtracted from TER measurements.
Experiments investigating the eﬀect of CSE on epithelial barrier
function were started when TER had reached at least 1000 X/cm2.
Aliquots of minimal essential medium (Gibco) supplemented with
100 U/ml penicillin (Gibco), 100 lg/mL streptomycin (Gibco) and
2 mM glutamine (Gibco), containing diﬀerent concentrations of
CSE were added either to the upper chamber (addition of 160 ll) or
to both the upper (addition of 160 ll) and lower chambers (addition
of 480 ll) of the transwell system, resulting in the exposure of
16HBE14o) monolayers to increasing doses of aqueous CSE (2%,
4%, 8%, 16% and 32%). These experiments were conducted once in
duplicate and once in quadruplicate wells and were compared with
duplicate/quadruplicate control wells containing culture medium
without CSE. The experiments were then repeated with a lower
concentration range of CSE (2%, 4%, 6%, 8%, 10% and 12%)
three times in triplicate wells.
Quantification of cell death by using flow cytometry
The proportion of viable 16HBE14o) cells after incubation with
diﬀerent concentrations of CSE (0%, 2%, 4%, 8%, 16% and 32%)
was determined by using ﬂow cytometry (Beckman Coulter,
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Fullerton, CA, USA) using nuclear propidium iodide ﬂuorescence
dye (PI) (Alexis Biochemicals, Carlsbad, CA, USA). Cells were
incubated with diﬀerent concentrations of CSE for 3 h at 37C in a
humidiﬁed atmosphere containing 5% CO2. Cells were then tryps-
inized to detach them from the cell culture ﬂask bottom, washed
with PBS and stained with PI according to the manufacturers
instructions. Necrotic cells are permeable for PI. Cell debris and
small matter were excluded from the analysis.
Immunocytochemistry
Cells were cultured on tissue culture slides (BD, Franklin Lakes, NJ,
USA) and exposed to diﬀerent concentrations of CSE (4%, 8% and
16%) for 3 h. After ﬁxation with acetone/methanole (1 : 1), they
were stained with a polyclonal rabbit IgG antibody against ZO-1
(Atlas Antibodies, Stockholm, Sweden) and an FITC-marked sec-
ondary antibody (Alexa Fluor 546, Molecular Probes, Carlsbad,
CA, USA) according to the manufacturers instructions and were
examined with a confocal laser scanning microscope (LSM 5 Exciter
Laser Scanning Microscope; Zeiss, Oberkochen, Germany).
Quantification of trans-epithelial allergen migration
Recombinant Bet v 1 (17 kDa), the major birch pollen allergen, and
recombinant Phl p 5 (28 kDa), a major timothy grass pollen aller-
gen, were obtained from Biomay (Vienna, Austria). Recombinant
house dust mite allergen Der p 2 (14 kDa) was produced as
described (31). Puriﬁed allergens were 125I labelled by using the
chloramin T method (32). 125I-labelled allergens (250 000 cpm/well)
were added to the upper chamber of the transwell system after
incubation of cells with CSE (2%, 4%, 8%, 16% and 32%) or
medium alone for 1 h added to either the upper or both the upper
and lower chambers. Two hours thereafter aliquots from the upper
and lower chambers were analysed in a gamma counter (Wallac,
Turku, Finland). Cells were removed from the membrane and lysed
for determination of intracellular radioactivity. Counts per minute
were determined for both chambers and the cell layer. All experi-
ments and measurements were performed in duplicates.
Basophil histamine release experiments
Transwell cell culture monolayers were incubated with increasing
dilutions of CSE (2%, 4%, 8%, 16% and 32%) or medium alone for
1 h, added to either the upper or both the upper and lower chambers.
Subsequently, 50 ng of rBet v 1 was added to the upper chamber.
After 3 h, aliquotswere removed from the lower chamber for basophil
histamine release experiments. Basophils from two diﬀerent patients
with sensitization toBet v 1were isolated using dextran sedimentation
and exposed to 100 ll of culture medium from the lower chamber
(33). For control purposes, basophils were incubated with various
concentrations of rBet v 1 (0.1–0.01 lg/ml) andwith aliquots of lower
chambers that had been incubated with CSE without the addition of
Bet v 1 or with medium alone. Release of histamine was measured
with RIA (Immunotech, Marseille, France) and is expressed as a
percentage of total histamine release. Transwell experiments to study
the eﬀects of rBet v 1 penetration on basophil release were performed
in duplicate wells. Histamine release experiments and measurements
were performed in triplicates.
Cytokine measurements
Transwell cell culture monolayers were incubated with increasing
dilutions of CSE (2%, 4%, 8%, 16% and 32%) or medium alone
for 24 h, added to both the upper and lower chambers. Before the
addition of CSE, 3 and 24 h after the addition of CSE, aliquots of
cell culture medium (100 ll) were taken and stored at )70C. The
concentrations of the cytokines, IL-1b, IL-2, IL-4, IL-5, IL- 6, Il-8,
IL-10, IL-12, IL-13, IFN-c, TNF-a and GM-CSF, secreted into the
upper and lower compartments by the HBE cell layer before and
after the addition of CSE were measured using the xMAP Luminex
ﬂuorescent bead-based technology (R&D Systems, Minneapolis,
MN, USA) according to the manufacturers instructions and ﬂuo-
rescence signal was read on Luminex 100 System (Luminex Corp.,
Austin, TX, USA).
Statistical analysis
Endpoints were analysed by an analysis of variance with linear
contrasts for comparison of CSE concentrations against controls.
Data were arcsine transformed to obtain homogeneity of variance.
For histamine release, patients and wells were considered random
factors. For all statistical analyses, values of P < 0.05 were con-
sidered signiﬁcant.
Results
Cigarette smoke extract decreases trans-epithelial resistance of
human respiratory epithelial cells
We examined whether exposure to CSE aﬀects the
epithelial barrier function of human 16HBE14o) bron-
chial epithelial cell monolayers. In Fig. 1A, the develop-
ment of TER after the addition of diﬀerent CSE
concentrations to the upper and lower chambers is
displayed. After 3 h of incubation with 8%, 16% and
32% of CSE, the TER dropped sharply and signiﬁcantly
(8%, 16% and 32% of CSE: P < 0.01). Lower CSE
concentrations (2% and 4%) did not have a relevant
inﬂuence on TER when compared with incubation with
medium alone. A similar eﬀect was seen after incubation
for 7 and 24 h. In Fig. 1B, the development of TER
between 2% and 12% of CSE is shown in greater detail.
It can be seen that the observed drop in TER after 3 h of
incubation already starts at a CSE concentration of 6%.
In a similar experiment, diﬀerent CSE concentrations
were added exclusively to the upper chamber of the
transwell system. A drop in TER was seen after 3 h of
incubation with 16% (61% reduction) and 32% of CSE
(complete loss of TER) but not with 8% of CSE. This
eﬀect was consistently seen also after 7 and 24 h of
incubation (data not shown).
In order to determine whether 16HBE14o) cells were
viable at theCSE concentrations used in these experiments,
ﬂow cytometric analyses were performed using propidium
iodide as a marker for cell necrosis. A slight increase in the
proportion of necrotic cells was seen after 3 h of incubation
with 8% of CSE (Table 1). After incubation with 16% and
32%of CSE, 55.5% and 74.4% of the cells stained positive
with propidium iodide respectively (Table 1). A repetition
of this experiment yielded similar results.
Similar levels of various cytokines (IL-1b, IL-2, IL-4,
IL-5, IL- 6, Il-8, IL-10, IL-12, IL-13, IFN-c, TNF-a and
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GM-CSF) were measured in the supernatants of
16HBE14o) cells 3 h after the addition of 2%, 4% and
8% of CSE or of culture medium alone. However, lower
levels of TNF-a, GM-CSF, IL-1b, IL-6 and IL-8 were
detected 3 h after the addition of 16% and 32% of CSE
when compared with the addition of culture medium
alone.
CSE induces morphological changes in 16HBE14o) cell monolayers
After 3 h of incubation with increasing concentrations of
CSE, cell contraction and a widening of intercellular gaps
were seen in the cell monolayer starting from a CSE
concentration of 4% (Fig. 2) as determined by using
phase contrast microscopy. Cell monolayers remained
unchanged upon incubation with cell culture medium
alone (Fig. 2) and with 2% of CSE. Immunostaining
for ZO-1 after 3 h of incubation with increasing
concentrations of CSE (4%, 8% and 16%) showed only
a slight alteration in the staining pattern (i.e. a slight loss
of continuity in the ZO-1 staining with increasing CSE
concentrations) when compared with the medium control
(data not shown).
A decrease in TER caused by CSE exposure is associated with
increased epithelial permeability for allergens
Wemeasured the permeability of the respiratory epithelial
cell layer for three diﬀerent allergens (rBet v 1, rPhl p 5
and rDer p 2) after incubation of cell monolayers with
various concentrations of CSE. Results from experiments
in which CSE was added to both the upper and lower
chambers are shown in Fig. 3. Incubation with 4% of CSE
did not substantially increase the permeability for the
allergens when compared with incubation with medium
alone. Permeability for Der p 2 and Phl p 5 was
signiﬁcantly increased after incubation with 8% of CSE
(Der p 2 and Phl p 5; Fig. 3). Permeability for Bet v 1 was
enhanced after incubation with 16% of CSE (Fig. 3).
A similar but less pronounced eﬀect on allergen perme-
ability was seen when diﬀerent CSE concentrations were
added exclusively to the upper chamber (data not shown).
No radiolabelled allergens were detected in the cell layer,
indicating paracellular penetration (data not shown).
CSE exposure increases subepithelial allergen concentrations and
leads to augmented histamine release from sensitized basophils
We investigated whether the CSE-induced increase in
allergen concentrations in the lower chambers of transwell
cultures aﬀects immediate type allergic inﬂammation.
Transwell cultures of 16HBE14o) monolayers were incu-
bated with increasing concentrations of CSE in the upper
and lower chambers of the transwell system before 50 ng of
rBet v 1 was added to the upper chambers. Histamine
release experiments were performed by incubating baso-
phil granulocytes from two diﬀerent birch pollen allergic
patients (Fig. 4A and B) with allergen-containing aliquots
of culturemedium from lower chambers. Incubation of cell
monolayers with 8%ofCSE and above led to an increase in
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Figure 1. Exposure of an epithelial cell monolayer to cigarette
smoke extract (CSE) induces a decrease in trans-epithelial
resistance (TER). Increasing concentrations of CSE (2%, 4%,
8%, 16% and 32%) were added to the upper and lower cham-
bers of the transwell system containing conﬂuent monolayers of
16HBE14o) cells. Changes in TER (X/cm2; y-axis) are shown
for diﬀerent time points (x-axis). (A) The same experiment was
also repeated in a lower CSE concentration range (2%, 4%, 6%,
8%, 10% and 12%). (B) SEM are displayed.
Table 1. Induction of cell necrosis by cigarette smoke extract
% of propidium
iodide-positive cells
Medium 5.3
2% CSE 5.9
4% CSE 6.4
8% CSE 15.7
16% CSE 55.5
32% CSE 74.4
Cells were incubated with different concentrations of cigarette smoke extract (2%,
4%, 8%, 16% and 32%) or medium alone for 3 h and were then analysed with
propidium iodide (PI) staining and flow cytometric analysis. The percentages of
necrotic cells are displayed.
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the Bet v 1 concentration in the lower chambers which
induced an increase in histamine release from eﬀector cells
in both experiments (P < 0.01; Fig. 4A and B). Incuba-
tion with 2% and 4% of CSE yielded similar histamine
release as incubation with cell culture medium alone.
No histamine release was observed after incubation of
basophils with cell culturemedium containing 16%ofCSE
without the addition of allergen (Fig. 4).
Discussion
In this study, we used three major respiratory allergens
from birch pollen, grass pollen and the house dust mite to
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Figure 3. Cigarette smoke extract facilitates allergen penetra-
tion across epithelial cell layers. 16HBE14o) monolayers were
incubated with three diﬀerent concentrations of CSE (4%, 8%,
16%, diﬀerent shades of grey) in the upper and lower chambers
or medium alone (white bars) for 1 h. Subsequently, 125I-la-
belled recombinant Bet v 1, Phl p 5 or Der p 2 were added to the
upper chamber. The percentage of allergen that had penetrated
to the lower chamber after 2 h is displayed on the y-axis.
Experiments performed in duplicate wells are shown.
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Figure 4. Enhanced trans-epithelial allergen penetration caused
by cigarette smoke extract (CSE) exposure leads to an increase
in histamine release from sensitized basophils. Epithelial cell
layers were incubated for 1 h with diﬀerent concentrations of
CSE (2%, 4%, 8%, 16% and 32%; x-axis) or medium alone
(0%) before 50 ng of rBet v 1 was added to the upper chambers.
Media obtained from the lower chambers 3 h later were added
to sensitized basophils from two diﬀerent birch pollen allergic
patients (A,B). The percentage of total histamine release is
displayed on the y-axis. A control experiment without the
addition of rBet v 1 is shown on the left-hand side of the graphs.
Black and grey bars indicate the results obtained with super-
natants from duplicate wells of the transwell system. Histamine
release was measured in triplicates (error bars).
8% CSENo CSE
Figure 2. Cigarette smoke extract (CSE) induces morphological changes in conﬂuent monolayers of 16HBE14o) cells. Intercellular
gaps are seen in the 16HBE14o) monolayer after incubation with 8% of CSE for 3 h (right), but not after incubation with cell culture
medium (left).
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investigate the impact of cigarette smoke exposure on the
permeability of a respiratory epithelial cell layer. We
found that CSE led to a substantial impairment of the
barrier function of the respiratory epithelium and an
increased permeability for each of the three respiratory
allergens tested. The increased subepithelial allergen
concentration resulted in an augmented release of inﬂam-
matory mediators from basophil granulocytes which were
used as a surrogate for subepithelial eﬀector cells. This
result suggests that cigarette smoking damages the
respiratory epithelial barrier and allows allergens to
intrude more eﬃciently into the subepithelial tissues
where they may cause increased allergic inﬂammation
through activation of various immune cells, among them
mast cells, T cells and eosinophils.
Our in vitro data thus suggest that cigarette smoke-
enhanced allergen penetration may be a factor for the
increased lung inﬂammation observed in mice which had
been exposed to allergen in conjunction with cigarette
smoke (18).
Cigarette smoke-enhanced allergen penetration
through the respiratory epithelium would also explain
observations that mice which are exposed to smoke
become more easily sensitized to respiratory allergens,
although a possible adjuvant activity may also play a role
(19).
We have recently found that respiratory allergen
contact strongly boosts the secondary IgE response to
allergens and allergen-speciﬁc sensitivity (34). Another
recent study reported that nasal challenge with environ-
mental tobacco smoke together with allergen increased
allergen-speciﬁc IgE production in the nasal lavage ﬂuids
of allergic patients and exacerbated allergic airway
disease (20). This ﬁnding may also be explained by our
data because cigarette smoke-enhanced allergen penetra-
tion may lead to increased stimulation of allergen-speciﬁc
IgE- and cytokine-producing cells in addition to a
possible adjuvant eﬀect of cigarette smoke.
It is likely that the inconsistent epidemiology of
smoking and the development and severity of type I
allergy mentioned in the introduction may be explained
by the fact that smoking can impact on allergic disease via
two main diﬀerent mechanisms: ﬁrst, a modulatory eﬀect
of smoking on the immune response was described (35).
This is illustrated for example by the decreased prevalence
of hypersensitivity pneumonitis in smokers when com-
pared with that in nonsmokers (36). Second, cigarette
smoke was shown to have a direct inﬂuence on
respiratory epithelial and alveolar cells (21–25). In
hypersensitivity pneumonitis, higher airway permeability
and damage to the air–blood barrier were found (37, 38)
and smoking was linked to a chronic progression of the
disease (39). Our own data show that smoking can reduce
the barrier function of the epithelium and may thus allow
substantially increased allergen penetration, thus result-
ing in higher IgE levels and a higher incidence of allergic
sensitization in certain populations (10–12, 14–16).
Our model allows to test directly the eﬀects of cigarette
smoke on the penetration of deﬁned allergens through the
respiratory epithelium and is not inﬂuenced by nonaller-
genic components, such as proteases which may be
present in certain allergen sources (e.g. house dust mite
extracts) but not in others. In this context, several
allergen source-derived factors were identiﬁed which
either promote the migration of allergens through the
epithelium (23) or bias the development of immune
responses towards Th2 (40).
Our experiments were performed with dilutions of
CSE containing nicotine concentrations of 14.1 (32% of
CSE) to 0.9 ng/ml (2% of CSE), which is comparable
with plasma nicotine concentrations of smokers (30).
Given the fact that nicotine and other components of
cigarette smoke have to diﬀuse into the blood from the
airways, it is unlikely that respiratory mucus contains
lower concentrations of smoke components than the
blood. Furthermore, it has been shown that the saliva of
smokers contains even higher nicotine concentrations
after consumption of two cigarettes (41). The CSE
concentrations we used may therefore be expected
in vivo. It is quite possible that at higher CSE concen-
trations the damage in the respiratory epithelium may be
less pronounced due to the clearing function of the cilial
activity in vivo compared with the in vitro cultured
epithelial cells; still the necrotic eﬀect in medium is
approximately 5.3% and increases only to 15.7% at 8%
of CSE and thus is actually quite small. We found only
a slight loss of continuity in the ZO-1 staining after CSE
exposure suggesting that the perturbation of tight
junctions does not play a major role in CSE-enhanced
allergen penetration.
Another advantage of the in vitro system used by us is
that it takes into account the covering protective lining of
aqueous mucus present in the human airways where
cigarette smoke may be enriched.
In conclusion, we have demonstrated that concentra-
tions of cigarette smoke comparable with those found in
smokers impair the barrier function of the respiratory
epithelium which allows greater concentrations of aller-
gens to penetrate. This may contribute to the exacerba-
tion of allergic disease by aggravating airway symptoms
and by boosting the IgE memory response.
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